

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

1. Personal Data:

Work: (206) 667-4077

Fax: (206) 667-4310

Email: smeshinc@fredhutch.org

Date of Birth: November 23, 1962

Citizenship: United States

Languages spoken: English and Persian

2. Education:

1980-1984 B.S.

1985-1990 The University of Michigan, Ann Arbor, MI, major in Microbiology
Ph.D.
The University of Michigan School of Medicine, Ann Arbor, MI
Dissertation: *Mechanism of regulation of glucocorticoid receptor transformation to the DNA-binding state by the endogenous metal stabilizing factor*

1990-1994 M.D.
Wayne State University School of Medicine, Detroit, MI

3. Postgraduate Training:

1994-1997 Pediatric Residency, Johns Hopkins Medical Institute, Baltimore, MD

1997-2000 Fellow, Department of Pediatrics, Division of Hematology/Oncology, jointly appointed at the Fred Hutchinson Cancer Research Center, University of Washington Medical Center, and Seattle Children's Hospital and Regional Medical Center

4. Faculty Positions Held:

2000-2002 Research Associate, Fred Hutchinson Cancer Research Center, Seattle, Washington

2000-2005 Acting Instructor, Department of Pediatrics, Division of Hematology/Oncology, University of Washington

2002-2005 Associate in Clinical Research, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

2005-2009 Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, University of Washington

2005-2009 Assistant Professor, Fred Hutchinson Cancer Research Center, Seattle, Washington

2009-2014 Associate Professor, Department of Pediatrics, Division of Hematology/Oncology, University of Washington

2009-2014 Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

05/2014 Professor, Department of Pediatrics, Division of Hematology/Oncology, University of Washington

07/2014 Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

5. Hospital Positions Held:

Seattle Children's Hospital, Pediatric Hematology/Oncology, 7/2000 - present
Fred Hutchinson Cancer Research Center, Pediatric Stem Cell Transplantation, 7/2000 - present

6. Honors:

1999 Jose Carreras Leukemia Foundation Young Investigator Award
1999 Child Health New Investigator Award
2002 COG Young Investigator Award

7. Board Certification:

Diplomate, American Board of Pediatrics, 1997
Board certified in Pediatric Hematology/Oncology, 11/2000, Re-certified 2009
Neonatal Advanced Life Support certification

8. Licensure:

2012 – 2020 Washington State Medical License #MD00036272

9. Professional Organizations:

American Chemical Society (ACS), 1982 – 1987
The University of Michigan Baha'i Club, 1981–1990. Chairman 1984 – 1988
District Teaching Committee, Mainland, Michigan, 1986 – 1991
American Medical Student Association (AMSA), 1991 – 1995
Physicians for Social Responsibility (PSR), 1991 – present. Coordinator, 1993 – 1995
International Health Coordinator, 1993 – 1995
American Medical Association (AMA), 1991 – 1997
American Academy of Pediatrics (AAP), 1994 – present
American Society of Hematology (ASH), 1998 – present
American Society of Clinical Oncology (ASCO), 1998 – present
American Society of Pediatric Hematology/Oncology (ASPH/O), 2000 – present

10. Teaching Experience:

Teaching Assistant, Genetics 305, The University of Michigan, 1982.
Teaching Assistant, Pharmacology 210 (Nursing Pharmacology), The University of Michigan, 1987–1988.
Student tutor, Medical Pharmacology; Wayne State University School of Medicine, 1991–1992.
Student tutor, Physiology & Pathophysiology; Wayne State University School of Medicine, 1993–1994.
Basic Hematology & Evaluation of Complete Blood Count. Johns Hopkins Nursing School. April 1997.
Attending, Pediatric Hematology/Oncology and pediatric stem cell transplantation, Seattle Children's Hospital and Fred Hutchinson Cancer Research Center, Seattle, WA.

I am an Attending in Pediatric Hematology/Oncology and pediatric stem cell transplantation at Seattle Children's Hospital and the Fred Hutch where I have mentored pre-doctoral and postdoctoral trainees for decades the last 20 years, as listed below.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

Table: Pre-doctoral and Postdoctoral Trainees for the Past Ten Years

Name	Pre/ Post Doc	Training Period	Prior Academic Degree			Area mentored	Current Position
			Type(s)	Year(s)	Institutions(s)		
Phoenix Ho	Post	2006-2014	MD	2003	Northeast Ohio	Research	Medical Director, Seattle Genetics
Fabiana Ostronoff	Post	2009-2015	MD	2003	Universidade Federal de Sao Paulo, Brazil	Research	Assistant Professor, University of Utah
Matthew Kutny	Post	2009-2011	MD	2005	Vanderbilt University	Research	Associate Professor, UAB
Heather Schuback	Post	2010-present	MD	2006	U of Utah School of Medicine	Research	Faculty, Seattle Children's Hospital
Katherine Tarlock	Post	2012-present	MD	2008	Rosalind Franklin Univ.	Research	Assistant Professor, Seattle Children's Hospital
Xiaoli Liu	Post	2007	MD	2000	China	Research	Professor, Beijing, China
Maya Hughes	Post	2010	MD, PhD	2009	Columbia University	Research	Attending Physician
Pilar Perdomo	Post	2011-12	MD	2009	Oviedo, Spain	Research	Faculty, Spain
Ranjani Ramamurthy	Pre	2012-2015	MS	1996	U of Wisconsin	Research	Medical Professional, Microsoft
Julia Kuhn	Pre	2013-2015	BA	2008	Wash U, St. Louis	Research	Ophthalmology, Univ. Pittsburgh
Shereen Khorami	Pre	2011				Research	Naturopathic Medical School
Vincent Lizzio	Pre	2011				Research	Medical School, WSU
Rabiah Ahmad	Pre	2014				Research	Medical Technologist
Alex Kostrinsky	Pre	2013-2015				Research	Graduate, UW
Dalia Selim	Post	2015-2018				Research	Post-doctoral Fellow, FHCRC
Maya Hughes	Post	2013 – 2015	MD, PhD	2009	Columbia University	Research	Attending Physician

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

Table: Pre-doctoral and Postdoctoral Trainees for the Past Ten Years

Name	Pre/ Post Doc	Training Period	Prior Academic Degree			Area mentored	Current Position
			Type(s)	Year(s)	Institutions(s)		
Kassra Taghizadeh	Pre	2015				Research	Student, University of Minnesota
Mahalaxmi Elango	Pre	2015 – 2016				Research	Student, MIT
Mollie (Eva) Hansen	Pre	2015 – 2017				Research	Student, University of Rochester
Jenny Smith	Post	2016-present				Research	Bioinformatic Staff, FHCRC
Emilia Lim	Post	2015-2017	PhD	2015	British Columbia University	Research	Faculty, Oxford University, London
Melinda Biernackie	Post	2015-2017	MD, PhD.	2014		Research	Faculty, FHCRC
Allison Kaeding	Post	2016 – present	MD	2012	Johns Hopkins University	Research	Senior Fellow
Leela Sarukkai	Pre	2017-present				Research	Student Intern
Grace Chang	Pre	2018				Research	Student Intern
Jake Appelbaum	Post	2018– present	MD, PhD	2016		Research	Senior Fellow
Amanda Leonti	Pre	2018 – present			OHSU	Research	Student Research Bio- Informatics Intern
Makia Manselle	Pre	2019-present				Research	Student Intern
Sophia Meshinchi	Pre	2019-present				Research	Student Intern
Ambria Johnson	Pre	2019-present				Research	Student Intern
Rula Green-Gladden	Post	2019-present	MD	2016		Research	Fellow
Lisa Wei	Pre	2018-Present	Ph.D.		Univ. Brit. Colu.	Research	Ph.D. Student

- Mentor for the following junior faculty:

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

1. Jessica Pollard – Associate Professor, University of Maine (Research)
2. Phoenix Ho, Assistant Professor, Seattle Children’s Hospital (Research)
3. Matthew Kutny – Associate Professor, University of Alabama (Research)
4. Michele Redell – Associate Professor, Baylor College of Medicine (Research)
5. Maria Gramatges – Assistant Professor, Baylor College of Medicine (Research)
6. Katherine Tarlock- Assistant Professor, Seattle Children’s Hospital (Research)
7. Melinda Biernackie – Acting Instructor, University of Washington (Research)
8. Adam Lamble – Assistant Professor, Seattle Children’s Hospital (Clinical)
9. Ann Dahlberg – Assistant Professor, Fred Hutchinson Cancer Research Center (Research)
10. Allie Kaeding – Acting Instructor of Pediatrics, University of Washington (Research)
11. Jake Appelbaum, Acting Instructor, University of Washington (Research)
12. Quy Le – Staff Scientist, Fred Hutchinson Cancer Research Center (Research)
13. Benjamin Huang; Assistant Professor, University of California, San Fransisco (Research)

11. Editorial Responsibilities:

2009-2015 Associate Editor, Pediatric Blood and Cancer

2016-present Member, PDQ Pediatric Treatment Editorial Advisory Board

Grant reviewer for: NCI SPORE (ad hoc reviewer); Leukemia Lymphoma Society (TRP and SCOR grants); St. Baldrick’s Consortium (consortium and YI grants); Hyundai Hope on Wheels; ALSF; Alex’s Lemonade Stand;

Manuscript reviews for: Journal of Clinical Oncology; Blood; Leukemia; Blood Advances; Lancet Oncology; Cell;

International Responsibilities:

2017-present Member, Scientific Advisory Committee, Personalized Oncogenomics (POG) Program at the British Columbia Cancer Agency Genome Sciences Center

2017-present International Society of Pediatric Oncology, Scientific Advisory Committee

12. Special National Responsibilities:

2000-2005 Study Committee Member, COG ALL Biology Study (AALL01B1)

2001-2005 Committee Member, AALL01B1 Study of minimal residual disease in ALL

2001-2010 Chairman, AML biology study, Role of class III tyrosine kinase receptor mutations in pediatric AML.

2002-2007 Committee Member, AAML0123- A Phase II Study of Gleevec in Ph+ Chronic Phase Chronic Myelogenous Leukemia

2002-present COG- Myeloid Disease Steering Committee

2002-2006 COG Infant Leukemia Task Force, Biology and Infant Issues Steering Committee

2003-2007 COG Young Investigator Committee

2003-2008 AAML03P1- Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study

2004-2012 Co-Director, COG AML Cell and Nucleic Acid Repository

2004-2018 Co-Director, COG Myeloid Resource Laboratory

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- 2004-2018 Lead Biologist, AAML0631, Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide during Consolidation
- 2004-2018 COG Relapsed AML Committee
- 2005-2015 Lead Biologist, COG AAML0531- A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
- 2007-2018 Biology Committee Member, COG AAML06P1- A Pilot Study of Lestaurtinib (CEP-701) in Combination with Chemotherapy in Young Patients with Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia
- 2007-2011 Vice Chair, COG AAML1031, Phase III AML study
- 2008-2018 AAML05P1- Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) and Newly Diagnosed AML with Monosomy 7 of -5/5q- in Children, Protocol Committee Member
- 2008-present Grant Reviewer, Alex's Lemonade Stand Foundation
- 2009-present Vice-Chair, COG Myeloid Disease Committee
- 2009-present Chair, COG Myeloid Disease Biology Committee
- 2009-2013 Co-Director, COG AML Cell and Nucleic Acid Repository
- 2009-2017 Director, Integrated Research Pathway, Seattle Children's Hospital
- 2012-2017 Member, 2nd NCI International Workshop Task Force Subcommittee
- 2012-present Director, COG Integrated Translational Science Center
- 2013-present Director, COG AML Cell and Nucleic Acid Repository
- 2013-present Member, COG Scientific Council
- 2014-present Member, Scientific Committee on Myeloid Neoplasia, American Society of Hematology (ASH)
- 2014-present Member, COG Executive Committee
- 2015-present Member, American Joint Commission on Cancer
- 2016-present Director, Target Pediatric AML (TpAML) initiative
- 2018-present Director, Discovery and Biomarker team; LLS Pediatric Acute Leukemia Initiative
- 2019-present Chair, Scientific Committee on Myeloid Neoplasia, American Society of Hematology (ASH)
- 2019-present Director, COG Hematopoietic Integrated Translational Science Center (HM-ITCS)
- 2019-present Senior Leadership Council Member, NCI Myeloid Neoplasms Precision Medicine Initiative

13. Special Local Responsibilities:

- 1998-2002 Principal Investigator, CHMC-ALL/B003 institutional study. Flow cytometric evaluation of early response to therapy in pediatric ALL.
- 2001-2002 Principal Investigator, Phase I trial of STI571 in Ph+ Leukemia
- 2001-2002 Co-investigator, FHCRC protocol 1555; Gemtuzumab Ozogamicin (GO), Fludarabine, and Low- Dose TBI Followed by Donor Stem Cell Transplantation for Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
- 7/2001-2005 Principal Investigator, Phase I trial of FTI R115777 in refractory leukemia
- 2003-2004 Principal Investigator, Phase I trial of FLT3 tyrosine kinase inhibitor L-000021649 in refractory Leukemia.
- 3/2003-2005 Principal Investigator, Phase II trial of STI 571 in pediatric patients with CML
- 2003-2006 Principal Investigator, Pediatric AML phase III trial

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- 2004-2006 Principal Investigator, COG AML pilot protocol
 2004-present Director, Pediatric Myeloid Diseases, Seattle Children's Hospital
 2005-2015 Director, Hematopathology Conference, Seattle Children's Hospital
 2010-present Director, Integrated Research Pathway, Seattle Children's Hospital
 2015-2017 Co-Chair, Consortium Scientific Review Committee, Fred Hutchinson Cancer Research Center
 2015-present Data Safety and Monitoring Committee, Clinical Research Division, Fred Hutchinson Cancer Research Center
 2015-present Executive Research Committee, Clinical Research Division, Fred Hutchinson Cancer Research Center
 2017-present Executive Leadership Committee, Division of Pediatric Hematology Oncology, Seattle Children's Hospital
 2019-present Lead in developing a program in hematologic malignancies and establishing a pediatric oncology presence, Global Oncology Program at the Uganda Cancer Institute

14. Research Funding:**Current** (*chronologic from date of award*)

- 03/01/2014 – 02/28/2021 Sponsor: Children's Hospital of Philadelphia /The Children's Oncology Group Foundation
 Title: Children's Oncology Group NCTN Network Group Operations
 Award: Salary support
 Role: Scientific Council Member and AML Committee Vice Chair
- 01/01/2016 – 12/31/2021 Sponsor: SRA/Hematologics
 Title: Defining Immunophenotypes of Pediatric Acute Myeloid Leukemias
 Total Costs: \$235,188
 Role: P.I.
- 04/01/2016 – 03/31/2021 Sponsor: NIH
 Title: Novel Biomarkers to Risk-Stratify AML Patients with NPM1^{Pos}/FLT3-IT^{Neg} Genotype
 Total Costs: \$2,523,360
 P.I.: Stirewalt
 Role: Co-Investigator
- 10/01/2017 – 02/28/2021 Sponsor: Alex's Lemonade Stand Foundation
 Title: Establishing the Function of Novel MicroRNAs Associated with Resistance and Relapse in Pediatric AML
 Total Costs: \$250,000
 P.I.: Oehler
 Role: Co-Investigator
- 10/18/2018 – 04/30/2021 Sponsor: Pfizer/University of Washington UWSC10837
 Title: Fractionated gemtuzumab ozogamicin to eradicate measurable residual disease in acute myeloid leukemia patients (GO for MRD)
 Total Costs: \$88,018
 P.I.: Percival, M.
 Role: Co-Investigator
- 03/01/2019 – 02/29/2021 Sponsor: NIH/NCI / Sub to Children's Hospital of Philadelphia, PO20074108-RSUB (ITSC)

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

05/01/2019 – 04/30/2099	Title: COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children Award: Salary support Role: Heme ITSC Chair Sponsor: Various
07/01/2019 – 12/31/2021	Title: Project Stella: Project 1 Functional Assessment of High-Risk Fusions in AML Total Costs: \$109,898 Role: P.I. Sponsor: Wipe Out Kids Cancer Foundation
07/01/2019 – 06/30/2022	Title: Target Pediatric AML (TpAML) Project Total Costs: \$100,000 Role: P.I. Sponsor: Leukemia Lymphoma Society
07/30/2019 – 07/29/2020	Title: Novel Immunotherapeutic Strategies in Infants with High-Risk AML Total Costs: \$600,000 Role: P.I. Sponsor: Leukemia Lymphoma Society
07/01/2019 – 06/30/2022	Title: PedAL Initiative Total Costs: \$20,000 Role: P.I. Sponsor: Leukemia Lymphoma Society / Sub to University of Florida
09/05/2019 – 09/04/2021	Title: Personalizing CD33-Directed Immunotherapy for Pediatric AML Total Costs: \$35,193 Role: P.I. Sponsor: Leukemia Lymphoma Society / Sub to The V Foundation
10/01/2019 – 07/31/2021	Title: Assessing the Canine Model of Acute Leukemia Total Costs: \$66,834 Role: P.I. Sponsor: NIH UG1 CA233249
10/01/2019 – 07/31/2021	Title: COG NCTN Integrated Translational Science Center for Hematopoietic Malignancies in Children Total Costs: \$4,794,327 Role: P.I. Sponsor: Children's Hospital of Philadelphia /The Children's Oncology Group Foundation
10/01/2019 – 09/30/2021	Title: Comprehensive Genomic Profiling to Improve Prediction of Clinical Outcome for Children with T-cell Acute Lymphoblastic Leukemia Total Costs: \$122,494 Role: P.I. Sponsor: The Children's Oncology Group Foundation (ITSC)
	Title: Validation of Therapeutic Targeting of Activating FLT3 Mutations by Gilteritinib Total Costs: \$50,000 P.I.: Tarlock

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

01/01/2020 – 12/31/2021	Role: Co-Investigator Sponsor: Fred Hutch/Global oncology pilot Title: Molecular landscape of acute leukemias in Uganda Total Costs: \$150,000 Role: P.I.
07/01/2020 – 06/30/2021	Sponsor: NIH/NCI - U01 CA232490 Supplement Title: Synergistic paired bispecific antibodies for CBF: GLIS-driven AML in infants and young children (PI: Olson, J) Role: Co-Investigator
10/01/2020 – 09/30/2022	Sponsor: Leukemia Lymphoma Society Title: Preclinical Immunotherapeutic Development in Childhood AML: Pathway to Rapid Clinical Translation Total Costs: \$600,000 Role: P.I.
01/01/2021 – 12/31/2021	Sponsor: Children's Oncology Group Title: Transcriptome Based Risk Determination in Pediatric AML: COG AAML1031 Correlative Study Total Cost: \$60,000 Role: P.I.
04/01/2021 – 03/31/2026	Sponsor: Children's Oncology Group Title: Biomarker, Imaging and Quality of Life Studies Funding Program: BIQSFP AAML1831 FLT3/ITD_Integral Testing Total Cost: \$133,380 Role: P.I.
08/01/2021 – 07/30/2025	Sponsor: American Cancer Society/St. Baldrick's Foundation Title: Integrated transcriptome-based prognostic and disease monitoring strategies in childhood AML Total Cost: \$800,000 Role: P.I.

Meshinchi Active (Mentored; no funding)

08/01/2017 – 07/31/2022	Sponsor: NIH/NCI Title: Pediatric Oncology Research Training Program Total Costs: \$1,306,125 P.I.: Co PD/PI
-------------------------	---

Past

09/30/1999 – 03/31/2004	Sponsor: NIH Title: Gene Expression Profile of Progression and Response in CML Role: Co-Investigator
07/01/2000 – 06/30/2002	Sponsor: Child Health Research Center Title: New Investigator Award in Pediatrics Role: P.I.
07/01/2000 – 06/30/2002	Sponsor: NCI Title: Career Development in Pediatric and Medical Oncology Role: K12 Scholar Investigator
07/01/2000 – 06/30/2003	Sponsor: Jose Carreras International Leukemia Foundation

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

	Title: Young Investigator Award Role: P.I.
09/01/2002 – 08/31/2010	Sponsor: COG YI Title: Identification of High-Risk AML Patients Using Receptor Tyrosine Kinase Mutational Analysis Role: P.I.
07/01/2003 – 06/30/2004	Sponsor: SCH Title: Evaluation of FLT3 kinase inhibitor L 000021649 in pediatric Leukemias Role: P.I.
07/07/2003 – 02/29/2012	Sponsor: NCI/NCCF Title: Biomarkers for Risk Identification and Risk-Based Therapy in Pediatric AML Role: Project PI
07/07/2003 – 02/29/2012	Sponsor: NCI/NCCF Title: Target Supplement Role: Project PI
07/07/2003 – 02/28/2014	Sponsor: NCI/CHO Title: Children's Oncology Group Role: Co-Investigator
08/08/2003 – 07/31/2006	Sponsor: NIH/NCI Title: Prognostic significance of FLT3 mutations in AML Role: P.I.
07/01/2004 – 06/30/2005	Sponsor: SCH Title: Evaluation of HSP90 as a Therapeutic Target in Pediatric AML Role: P.I.
07/01/2004 – 06/30/2006	Sponsor: COG-TRI Title: Utility of Gene Expression Levels in Identification of High-Risk AML Patients Role: P.I.
07/01/2004 – 06/30/2006	Sponsor: NIH/NCI Title: Accurate Prediction of Acute Myeloid Leukemia Relapse Using Multidimensional Flow Cytometry Role: P.I.
08/01/2005 – 07/31/2011	Sponsor: NIH/NCI Title: Biology and Prognostic Implications of FLT3 Mutations in AML Role: P.I.
09/15/2005 – 05/31/2010	Sponsor: NIH Title: Leukemia Signatures for Risk Classification and Targeting Role: Co-Investigator
04/01/2008 – 03/31/2010	Sponsor: NIH/NCI Title: Children's Cancer Study Group (subcontract to FHCRG) Role: Co-Investigator
02/01/2009 – 01/31/2012	Sponsor: COG TE 5139 Title: Molecular Assessment of Minimal Risk in Acute Promyelocytic Leukemia Role: Investigator

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- 11/01/2009 – 10/31/2010 Sponsor: CCEH
Title: Pilot Study: “Validating Susceptibility Genes for Acute Myeloid Leukemia (AML)”
Role: Pilot Project P.I.
- 01/01/2010 – 12/31/2010 Sponsor: NIH
Title: Pilot Study: “Single Cell Genomic Profiling in Cancer”
Role: Investigator
- 11/11/2010 – 11/30/2015 Sponsor: CRA – EISAI 000012
Title: A Randomized Open Label Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming with Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia AML
Subjects: Correlative Biology Studies
Role: P.I.
- 02/01/2011 – 01/31/2016 Sponsor: NIH/NCI
Title: Stem Cells, Differentiation and Therapeutic Resistance in AML
Role: Co-Investigator
- 04/01/2011 – 09/30/2015 Sponsor: NMDP
Title: 09-MRD Chimerism Lab Testing
Role: P.I.
- 07/01/2011 – 01/31/2014 Sponsor: St. Baldrick’s Foundation
Title: Ex Vivo Expanded Hematopoietic Progenitors for AML Supportive Care
Role: Co-Investigator
- 12/01/2011 – 11/30/2013 Sponsor: Hope On Wheels
Title: Identification of Novel Genomic Markers in AML
Role: P.I.
- 03/01/2012 – 02/28/2014 Sponsor: NIH/NCI
Title: Protein Biomarkers in Childhood Acute Myeloid Leukemia
Role: Co-Investigator
- 03/01/2012 – 02/28/2014 Sponsor: NIH NCCF
Title: Risk Based Therapy Allocation in Childhood AML (COG AAML1031)
Role: Co-Investigator
- 04/16/2012 – 04/30/2014 Sponsor: NIH
Title: Prognostic and Functional Significance of Adhesion Molecules in Pediatric AML
Role: Co-Investigator
- 05/01/2012 – 04/30/2013 Sponsor: Seattle Children’s Research Institute
Title: Novel Genomic Alterations in Childhood AML
Role: P.I.
- 05/01/2012 – 03/31/2017 Sponsor: NCI
Title: Discovery and Optimization of AML Prognostic Biomarkers
Role: Co-Investigator
- 07/01/2012 – 06/30/2014 Sponsor: St. Baldrick’s Foundation
Title: Exploiting WT1 Alterations in AML Target Identification and MRD Monitoring
Role: Mentor

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- 07/01/2012 – 06/30/2015 Sponsor: Alex’s Lemonade Stand Foundation
Title: Transcriptome Sequencing (RNA-Seq) for Identification of Novel Markers of Disease Outcome and Therapeutic Targets in Acute Myeloid Leukemia
Role: Mentor
- 08/01/2012 – 07/31/2015 Sponsor: Coltman Fellowship Award/Hope Foundation
Title: Transcriptome Sequencing (RNA-Seq) for Identification of Novel Markers of Disease Outcome and Therapeutic Targets in Patients with Acute Myeloid Leukemia
Role: Mentor
- 09/20/2012 – 07/31/2019 Sponsor: NIH/NCI
Title: Biology and Prognostic Implications of FLT3 Mutations in AML
Total Costs: \$2,190,033
Role: P.I.
- 07/01/2013 – 12/31/2014 Sponsor: ASCO
Title: Biologic and Clinical Implications of ETV6 Genomic Variations in AML
Role: Mentor
- 07/01/2013 – 06/30/2015 Sponsor: St. Baldrick’s Foundation
Title: Biologic and Clinical Implications of ETV6 Variants in Childhood AML
Role: Mentor
- 07/01/2013 – 12/31/2015 Sponsor: Alex’s Lemonade Stand Foundation
Title: Genomic alterations in ETV6 predict outcome in pediatric AML
Role: Mentor
- 09/01/2013 – 10/10/2015 Sponsor: NIH/NCI – Career Dev in Pediatric & Medical Oncology
Title: “Genomic Alterations in Nucleoporin Genes in AYA with Acute Myeloid Leukemia: Pathogenesis and an Opportunity for Targeted Therapy” (PI: Ostronoff, F.)
Role: Mentor
- 12/01/2013 – 05/31/2015 Sponsor: St. Baldrick’s Foundaton
Title: Establishment of a shared pediatric cancer molecular data portal for prediction of outcomes and treatment response to targeted therapies
Role: Co-Investigator
- 02/01/2014 – 01/31/2016 Sponsor: SCH
Title: Generation of Patient Derived ex vivo Testing Platform for High Throughput Drug Screening in Acute Myeloid Leukemia
Role: P.I.
- 03/01/2014 – 02/28/2018 Sponsor: NIH NCCF
Title: Risk Based Therapy Allocation in Childhood AML (COG AAML1031)
Role: Project Leader
- 03/01/2014 – 02/28/2019 Sponsor: CHOP/COG
Title: Children's Oncology Group NCTN Network Group Operations
Role: Project Leader
- 07/01/2014 – 06/30/2016 Sponsor: SAGE/St. Baldrick’s Foundation

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

	Title: The AML Federation Project: Coordinated AML treatment options using joint individualized systems medicine approaches
	Role: Co-Investigator
07/01/2014 – 06/30/2016	Sponsor: Alex's Lemonade Stand Foundation
	Role: Mentor
01/01/2015 – 12/31/2017	Sponsor: CHOP/St. Baldrick's
	Title: Validation of Mesothelin as a Therapeutic Target in Childhood AML
	Role: Mentor
07/01/2015 – 06/30/2016	Sponsor: St. Baldrick's Foundation
	Title: CSF3R Mutations as Targetable Drivers of Pediatric AML
	Role: P.I.
12/31/2015 – 12/30/2017	Sponsor: Hyundai Hope on Wheels
	Title: Novel Therapeutic Strategy in Relapsed FLT3/ITD Acute Myeloid Leukemia
	Role: Mentor
02/01/2016 – 01/31/2019	Sponsor: Alex's Lemonade Stand Foundation
	Title: Targeting Novel Pediatric-Specific FLT3 Mutations
	Role: P.I.
01/01/2016 – 05/30/2019	Sponsor: NIH
	Title: Cancer Center Support Grant (Comprehensive)
	Total Costs: \$47,796,425
	Role: Co-Investigator
07/01/2017 – 06/30/2020	Sponsor: St. Baldrick's Foundation
	Title: Mesothelin-directed Immunotherapeutic Targeting in Childhood AML
	Role: Mentor
07/01/2017 – 06/30/2019	Sponsor: NCI
	Title: Career Development in Pediatric and Medical Oncology
	Role: Mentor for Kaeding
07/01/2018 – 06/30/2019	Sponsor: ASCO, Conquer Cancer
	Title: Validation of Mesothelin as a Novel Disease Marker and Therapeutic Target in Acute Myeloid Leukemia
	P.I.: Kaeding, A.
	Role: Co-Investigator
07/01/2018 – 06/30/2019	Sponsor: Rally FND/Truth 365
	Title: Validation of Mesothelin as an Immunotherapeutic Target in Pediatric AML
	P.I.: Kaeding
	Role: Co-Investigator
06/01/2019 – 09/30/2019	Sponsor: St. Baldrick's Foundation Summer Fellowship Program
	Title: Verification and validation of newly discovered immunotherapeutic targets in childhood AML
	Total Costs: \$5,000
	Role: P.I./Mentor
05/01/2019 – 12/31/2019	Sponsor: The Children's Oncology Group Foundation (ITSC)
	Title: Therapeutic Targeting of Mesothelin in Pediatric AML

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

P.I.: Kaeding
Role: Co-Investigator
02/23/2018 – 02/22/2020 Sponsor: SRA/Seattle Genetics
Title: SGN33A-001: Nucleic Acid Extraction, Genotyping, and Isoform Expression of CD33
Total Costs: \$81,468
Role: P.I.

02/23/2018 – 02/22/2020 Sponsor: SRA/Seattle Genetics
Title: SGN33A-002: Nucleic Acid Extraction, SNP Identification, and Transcript Analysis of CD33
Total Costs: \$68,744
Role: P.I.

07/01/2015 – 03/31/2020 Sponsor: St. Baldrick's Foundation
Title: Pathway Directed Treatment for Refractory AML
Total Costs: \$2,500,000
Role: P.I.

01/15/2016 – 01/15/2020 Sponsor: Hyundai Hope on Wheels
Title: Devising Genomic Guided Immunotherapy for Childhood AML
Total Costs: \$1,000,000
Role: P.I.

06/01/2018 – 05/31/2020 Sponsor: NIH
Title: Germline and Somatic Variants in Myeloid Malignancies in Children
Total Costs: NA (NIH Resource Grant)
Role: P.I.

06/01/2020 – 09/30/2020 Sponsor: St. Baldrick's Foundation Summer Fellowship Program
Title: Verification and validation of immunotherapeutic targets in childhood AML
Total Costs: \$5,000
Role: P.I./Mentor

12/01/2017 – 11/30/2020 Sponsor: Leukemia Lymphoma Society
Title: Therapeutic Development of Mesothelin Antibody-Drug Conjugate Anetumab Revtansine in Mesothelin Expressing Childhood AML
Total Costs: \$426,357
Role: P.I.

02/01/2019 – 01/31/2021 Sponsor: Alex's Lemonade Stand Foundation "REACH"
Title: Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2- AML in Children
Total Costs: \$250,000
Role: P.I.

15. Bibliography

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

Research Papers:

*significant scholarly publications; **Authors contributed equally to the manuscript

1. Sanchez ER, **Meshinchi S**, Schlesinger MJ, Pratt WB: Demonstration that the 90-kilodalton heat shock protein is bound to the glucocorticoid receptor in its 9S nondeoxynucleic acid binding form. *Molecular Endocrinology* 1:908-912, 1987.
2. Tienrungroj W, **Meshinchi S**, Sanchez ER, Pratt SE, Grippo JF, Holmgren A, Pratt WB: The role of sulfhydryl groups in permitting transformation and DNA-binding of the glucocorticoid receptor. *Journal of Biological Chemistry* 262:6992-7000, 1987.
3. Sanchez ER, **Meshinchi S**, Tienrungroj W, Schlesinger MJ, Toft DO, Pratt WB: Relationship of the 90-kDa murine heat shock protein to the untransformed and transformed states of the L cell glucocorticoid receptor. *Journal of Biological Chemistry* 262:6986-6991, 1987.
4. **Meshinchi S**, Grippo JF, Sanchez ER, Bresnick EH, Pratt WB: Evidence that the endogenous, heat-stable glucocorticoid receptor stabilizing factor is a metal component of the untransformed receptor complex. *Journal of Biological Chemistry* 263:16809-16817, 1988.
5. **Meshinchi S**, Pratt WB: Evidence that removal of an endogenous metal that stabilizes the untransformed glucocorticoid receptor in cytosol allows ligand-independent receptor transformation. *Journal of Steroid Biochemistry* 34:315-317, 1989.
6. Pratt WB, Dalman FC, **Meshinchi S**, Scherrer LC: The relationship between glucocorticoid receptor binding to hsp90 and receptor function. *Japanese Journal of Endocrinology* 66: 1185-1197, 1990.
7. **Meshinchi S**, Sanchez ER, Martel K, Pratt WB: Elimination and reconstitution of the requirement for hormone in promoting temperature dependent transformation of cytosolic glucocorticoid receptor to the DNA-binding state. *Journal of Biological Chemistry* 265; 4863-4870, 1990.
8. **Meshinchi S**, Matic G, Pratt WB: Selective molybdate-directed covalent modification of sulfhydryl groups in the steroid binding versus the DNA-binding domain of the glucocorticoid receptor. *Journal of Biological Chemistry* 265:11643-11649, 1990.
9. Scherrer LC, Dalman FC, Massa E, **Meshinchi S**, Pratt WB: Structural and functional reconstitution of the glucocorticoid receptor-hsp90 complex. *Journal of Biological Chemistry* 265:21397-21400, 1990.
10. Hutchison K, Matic G, **Meshinchi S**, Bresnick EH, Pratt WB: Redox manipulation of DNA binding activity and BuGR epitope reactivity of the glucocorticoid receptor. *Journal of Biological Chemistry* 266:10505-10509, 1991.
11. **Meshinchi S**, Stancato LF, Gordon BM, Jones KW, Pratt WB: Purification of the endogenous glucocorticoid receptor stabilizing factor. *Biochemistry* 30:8617-8622, 1991
12. **Meshinchi S**, Woods, WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP: Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. *Blood* 97:89-94, 2001.
13. Stirewalt, DL, Kopecky, KJ, Meshinchi, S, Appelbaum FR, Slovak ML, Willman CL, Radich JP: FLT3, Ras and p53 mutations in elderly patients with acute myeloid leukemia. *Blood* 97: 3589-3595, 2001.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

14. **Meshinchi S**, Thomson B, Finn LS, Leisenring W, Green C, Radich JP, Loken M, Hawkins D: Comparison of multidimensional flow cytometry evaluation of early marrow response in pediatric acute lymphoblastic leukemia. *Journal of Pediatric Hematology Oncology* 23:585-590, 2001.
15. ****Meshinchi S**, ****Stirewalt DL**, Alonzo TA, Zhang Q, Sweetser DA, Woods WG, Bernstein ID, Arceci RJ, Radich JP. Activating mutations of RTK/*ras* signal transduction pathway in pediatric acute myeloid leukemia. *Blood* 102:1474-1479, 2003.
16. ****Meshinchi S**, ****Zwaan CM**, Radich JP, Veerman AJP, Huismans DR, Munske L, Podleschny M, Hählen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJL, Griesinger F. FLT3 Internal Tandem Duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. *Blood* 102:2387-2394, 2003.
17. Johnston DL, **Meshinchi S**, Oheim KE, Pallavocini MG, Feusner J, Woods WG, Lange, BJ, Radich, JP, Bernstein ID: Progenitor cell involvement is predictive of response to chemotherapy in acute myeloid leukemia. *British Journal of Haematology* 123:431-435, 2003.
18. **Meshinchi S**, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP, Sanders JE: Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. *Biology of Blood Marrow Transplantation* 9:706-713, 2003.
19. Stirewalt DL, **Meshinchi S**, Kussick SJ, Sheets K, Pogosova-Agadjanyan E, Willman CL, Radich, JP: Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. *British Journal of Haematology* 124:481-484, 2004.
20. Loh ML, Vattikuti S, Reynolds MG, Carlson EJ, Schubert S, Lieu KH, Cheng JW, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, **Meshinchi S**, Le Beau MM, Emanuel PD, Shannon KM: Somatic Mutations in *PTPN11* Implicate the Protein Tyrosine Phosphatase SHP-2 in Leukemogenesis. *Blood* 103:2325-2331, 2004.
21. ****Meshinchi S**, ****Brown P**, Levis M, Alonzo T, Gerbing R, Lange B, Arceci R, Small D: Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. *Blood* 104:1841-1849, 2004.
22. Thomson B, Park JR, Felgenhauer J, **Meshinchi S**, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS: Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. *Pediatric Blood and Cancer* 43:571-579, 2004.
23. Loh ML, Reynolds MG, Vattikuti S, Cheng J, Gerbing RB, Alonzo TA, Heerema N, Lange BJ, **Meshinchi S**: PTPN11 mutations in pediatric acute myeloid leukemia: results from Children's Cancer Group. *Leukemia* 18:1831-1834, 2004.
24. Lacayo NJ, **Meshinchi S**, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MJ, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV: Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. *Blood* 104:2646-2654, 2004.
25. ****Meshinchi S**, ****Tse W**, Alonzo TA, Stirewalt DL, Gerber RB, Woods WG, Appelbaum FR, Radich JP: Elevated expression of AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. *Blood* 104:3058-3063, 2004.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

26. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, **Meshinchi S**, Loonen AH, Hählen K, Reinhardt D, Creutzig U, Kaspers GJL, Heinrich MC: Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. *Leukemia* 19:1536-1542, 2005.
27. Stirewalt DL, Kopecky KJ, **Meshinchi S**, Engel JH, Pogossova-Agadjanyan EL, Linsley J, Slovak ML, Willman CL, Radich JP: Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. *Blood* 107:3724-3726, 2006. PMID: PMC1895777
28. Aplenc R, Alonzo TA, Gerbing RB, Smith FO, **Meshinchi S**, Ross JA, Perentesis J, Woods WG, Lange BJ, Davies SM: Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. *Blood* 108:74-80, 2006. PMID: PMC1895824
29. **Meshinchi S**, Arceci RJ, Sanders JE, Smith FO, Woods WB, Radich JP, Alonzo TA: Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. *Blood* 108:400-401, 2006.
30. Slovak ML, Gundacker H, Bloomfield CD, Dewald G, Appelbaum FR, Larson RA, Tallman MS, Bennett JM, Stirewalt DL, **Meshinchi S**, Willman CL, Ravindranath Y, Alonzo TA, Carroll AJ, Raimondi SC, Heerema NA: A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. *Leukemia* 20:1295-1297, 2006.
31. **Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA, Radich JP, Bernstein ID, **Meshinchi S****. FLT3 internal tandem duplication in CD34+/CD33- precursors predicts poor outcome in acute myeloid leukemia. *Blood* 108:2764-2769, 2006. PMID: PMC1895585
32. **Meshinchi S**, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ, Radich JP: Clinical implications of FLT3 mutations in pediatric AML. *Blood* 108:3654-3661, 2006. PMID: PMC1895470
33. **Meshinchi S**, Arceci RJ: Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. *Oncologist* 12:341-355, 2007.
34. Barbaric D, Alonzo TA, Gerbing RB, **Meshinchi S**, Heerema NA, Barnard DR, Lange BJ, Woods WG, Arceci RJ, Smith FO: Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and -2961. *Blood* 109:2314-2321, 2007. PMID: PMC1852193
35. Brown P, McIntyre E, Rau R, **Meshinchi S**, Lacayo N, Dahl G, Alonzo TA, Chang M, Arceci RJ, Small D: The incidence and clinical significance of nucleophosmin mutations in childhood AML. *Blood* 110:979-985, 2007. PMID: PMC1924773
36. Stirewalt DL, **Meshinchi S**, Kopecky KJ, Fan W, Pogossova-Agadjanyan EL, Engel JH, Cronk MR, Shannon Dorcy K, McQuary AR, Hockenbery D, Wood B, Heimfeld S, Radich JP: Identification of genes with abnormal expression changes in acute myeloid leukemia. *Genes Chromosomes and Cancer* 47:8-20, 2008.
37. Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, **Meshinchi S**, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group: DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. *Leukemia* 22:265-272, 2008. PMID: PMC2914507

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

38. **Meshinchi S**, Stirewalt DL, Alonzo TA, Boggon TJ, Gerbing RB, Rocnik JL, Lange BJ, Gilliland DG, Radich JP: Structural and numerical variation of FLT3/ITD in pediatric AML. *Blood* 111:4930-4933, 2008. PMID: PMC2384125
39. Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, **Meshinchi S**, Lange BJ, Davies SM: FAS Promoter Polymorphism: Outcome of Childhood Acute Myeloid Leukemia: A Children's Oncology Group Report. *Clinical Cancer Research* 14:7896-7899, 2008. PMID: PMC2787450
40. Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, **Meshinchi S**, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM: Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. *British Journal of Haematology* 144:388-394, 2008. PMID: PMC3083240
41. **Meshinchi S**, Appelbaum F: Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia. *Clinical Cancer Research* 15:4263-4269, 2009. PMID: PMC2716016
42. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Radich J, **Meshinchi S**: Prevalence and Prognostic Implications of CEBP μ Mutations in Pediatric Acute Myeloid Leukemia (AML): a report from the Children's Oncology Group. *Blood* 113:6558-6566, 2009. PMID: PMC2943755.
43. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y, Dahl G, Lacayo NJ, Becton D, Chang M, Weinstein HJ, Hirsch B, Raimondi SC, Heerema NA, Woods WG, Lange BJ, Hurwitz C, Arceci RJ, Radich JP, Bernstein ID, Heinrich MC, **Meshinchi S**: Prevalence and prognostic significance of KIT mutations in pediatric core binding factor AML patients enrolled on serial pediatric cooperative trials for de novo AML. *Blood* 115: 2372-2379, 2010. PMID: PMC2845895
44. Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA, Loken MR, **Meshinchi S**: High Expression of the Very Late Antigen (VLA) – 4 Integrin Independently Predicts Reduced Risk of Relapse and Improved Outcome in Pediatric Acute Myeloid Leukemia: a Report from the Children's Oncology Group. *Journal of Clinical Oncology* 28: 2831-8, 2010. PMID: PMC2903318
45. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Gerbing RB, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Reaman GH, Baker LH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, **Meshinchi S**: Molecular alterations of the *IDH1* gene in AML: a Children's Oncology Group and Southwest Oncology Group study. *Leukemia* 24: 909-13, 2010. PMID: PMC2945692.
46. Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA, Stirewalt DL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, **Meshinchi S**: Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. *Blood* 116:702-10, 2010. PMID: PMC2918327.
47. Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, **Meshinchi S**, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui C-H, Campana D: Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. *Lancet Oncol* 11: 543-52, 2010. PMID: PMC3171799

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

48. Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, **Meshinchi S**, Bhatla D, Radloff G, Davies SM: MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 55: 248-53, 2010. PMCID: PMC2915901
49. Pui C-H, Carroll WL, **Meshinchi S**, Arceci RJ: Biology, Risk Stratification and Therapy of Pediatric Acute Leukemias: An Update. *Journal of Clinical Oncology* 29:551-65, 2011. PMCID: PMC3071256
50. Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch BA, Franklin JL, Lange B, Gamis AS, Alonzo TA, **Meshinchi S**: WTI synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the Children's Oncology Group. *Journal of Clinical Oncology* 29: 704-11, 2011. PMCID: PMC3056655
51. Berman JN, Gerbing RB, Alonzo TA, Ho PA, Miller K, Hurwitz C, Heerema NA, Hirsch B, Raimondi SC, Lange B, Franklin JL, Gamis A, **Meshinchi S**: Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group. *Leukemia* 25: 1039-42, 2011.
52. Ho PA, Kutny MA, Alonzo TA, Gerbing RB, Joaquin J, Raimondi SC, Gamis AS, **Meshinchi S**: Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 57: 204-9, 2011. PMCID: PMC3115394
53. Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, **Meshinchi S**: Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. *Blood* 118: 4561-6, 2011. PMCID: PMC3208275
54. Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, **Meshinchi S**, Gamis A: AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: A report from the children's oncology group. *Cancer* 118: 761-9, 2012.
55. Kutny MA, Moser BK, Gregory J, Woods WG, Feusner JH, **Meshinchi S**: FLT3 Mutations are Prevalent and are Significantly Associated with Induction Death in Pediatric Acute Promyelocytic Leukemia, a Report from the Children's Oncology Group. *Pediatric Blood and Cancer* 59: 662-7, 2012. PMCID: PMC3368997.
56. Pollard JA, Alonzo TA, Loken M, Gerbing RB, Ho PA, Bernstein ID, Raimondi SC, Hirsch B, Franklin J, Walter RB, Gamis A, **Meshinchi S**: Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. *Blood* 119(16): 3705-11, 2012. PMCID: PMC3335378.
57. **Meshinchi S**, Hunger SP, Aplenc R, Adamson PC, Jessup JM: Lessons Learned From the Investigational Device Exemption (IDE) Review of Children's Oncology Group Trial AAML1031. *Clinical Cancer Research* 18(6): 1547-54, 2012. PMCID: PMC3310885.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

59. Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, **Meshinchi S**, Bhagavathula N, Varani J: Stimulation of fibroblast proliferation by insoluble gadolinium salts. *Biol Trace Elem Res* 145: 257-67, 2012. PMID: PMC3273605.
60. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, **Meshinchi S**: Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. *Blood* 120: 1581-8, 2012. PMID: PMC3429302.
61. Foss EJ, Radulovic D, Stirewalt DL, Radich J, Sala-Torra O, Pogossova-Agadjanyan EL, Hengel SM, Loeb KR, Deeg HJ, **Meshinchi S**, Goodlett DR, Bedalov A: Proteomic Classification of Acute Leukemias by Alignment-Based Quantitation of LC-MS/MS Data Sets. *J Proteome Res* 11: 5005-10, 2012. PMID: PMC3564549.
62. Creutzig U, van den Heuvel-Eibrink MM, Gison B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, **Meshinchi S**, Pession A, Raimondi SC, Sung L, Stary J, Zwan CM, Kaspers GJ, Reinhardt D; on behalf of the AML Committee of the International BFM Study Group: Diagnosis and management of acute myeloid leukemia in children and adolescents; recommendations from an international expert panel. *Blood* 120: 3187-3205, 2012.
63. Gudgeon CJ, Harrington KH, Laszlo GS, Alonzo TA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, **Meshinchi S**, Walter RB: High Expression of Neutrophil Elastase Predicts Improved Survival in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. *Leuk Lymphoma* 54: 202-4, 2013. PMID: PMC3757129
64. Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, **Meshinchi S**: Mutations of the DNMT3A Methyltransferase Domain Independently Predict Poor Outcome in Older Patients with Acute Myeloid Leukemia: A SWOG report. *Leukemia* 27(1):238-41, 2013.
65. Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Twardy DJ, **Meshinchi S**. FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. *Blood* 121(7):1083-93, 2013. PMID: PMC3575754.
66. Mortland L, Alonzo TA, Walter RB, Gerbing RB, Mitra AK, Pollard JA, Loken MR, Hirsch B, Raimondi S, Franklin J, Pounds S, Cao X, Rubnitz JE, Ribeiro RC, Gamis A, **Meshinchi S**, Lamba JK: Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy. *Clin Cancer Res* 19(6): 1620-1627, 2013. PMID: PMC3602123.
67. de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Beverloo HB, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmerman M, Alonzo TA, Pieters R, **Meshinchi S**, van den Heuvel-Eibrink MM, Zwaan CM: *NUP98/JARID1A* is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct *HOX*-gene expression pattern. *Leukemia* 27(12): 2280-8 2013.
68. Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC, Hirsch BA, Gamis AS, McIntosh MW, **Meshinchi S**: Significance of Expression of ITGA5 and its Splice Variants in Acute Myeloid Leukemia: A Report from the Children's Oncology Group. *Am J Hematol* 88: 694-702, 2013. PMID: PMC3757130.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

69. Ho PA, Alonzo TA, Gerbing RB, Pollard JA, Hirsch B, Raimondi SC, Cooper T, Gamis AS, **Meshinchi S**: High EVI1 Expression Is Associated with *MLL* Rearrangements and Predicts Decreased Survival in Paediatric AML: A Report From the Children's Oncology Group. *Br J Haematol* 162:670-677, 2013. PMID: PMC3754879.
70. Lacayo NJ, Alonzo TA, Gayko U, Rosen DB, Westfall M, Purvis N, Putta S, Louie B, Hackett J, Cohen AC, Cesano A, Gerbing R, Ravindranath Y, Dahl GV, Gamis A, **Meshinchi S**: Development and validation of single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with *de novo* acute myeloid leukaemia: a report from the Children's Oncology Group. *British Journal of Haematology*, 162: 250-262, 2013.
71. Ho PA, Alonzo TA, Gerbing RB, Kuhn J, Pollard JA, Hirsch B, Raimondi SC, Gamis AS, **Meshinchi S**: The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: a report from the Children's Oncology Group. *Pediatr Blood & Cancer* 61(1):81-8, 2014.
72. **Meshinchi S**: Hematopoietic Cell Transplantation in High-Risk Childhood Acute Myelogenous Leukemia. *Biol Blood Marrow Transplant* 19: 1002-1005, 2013.
73. Ostronoff F, Othus M, Kantarjian HM, **Meshinchi S**, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH: A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positively in patients with newly diagnosed acute myeloid leukemia. *Br J Haematol* 163:130-132, 2013. PMID: PMC4128010.
74. Pogossova-Agadjanyan EL, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, May JJ, Oehler VG, Petersdorf S, Pogosov GL, Radich JP, Willman CL, **Meshinchi S**, Stirewalt DL: The Prognostic Significance of IRF8 Transcripts in Adult Patients with Acute Myeloid Leukemia. *PLoS One* 8(8):e70812, 2013. PMID: PMC3743845.
75. Canner J, Alonzo TA, Franklin J, Freyer DR, Gamis A, Gerbing RB, Lange BJ, **Meshinchi S**, Woods WG, Perentesis J, Horan J: Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients. *Cancer* 119(23):4162-9, 2013. PMID: PMC4398142.
76. Morris VA, Zhang A, Yang T, Stirewalt DL, Ramamurthy R, **Meshinchi S**, Oehler VG: MicroRNA-150 Expression Induces Myeloid Differentiation of Human Acute Leukemia Cells and Normal Hematopoietic Progenitors. *PLoS One*: 24;8(9):e75815, 2013 PMID: PMC3782459.
77. Ochs MF, Farrar JE, Considine M, Wei Y, **Meshinchi S**, Arceci RJ: Outlier Analysis and Top Scoring Pair for Integrated Data Analysis and Biomarker Discovery. *IEEE/ACM Trans Comput Biol Bioinform*, Nov 22, 2013. PMID: PMC4156935
78. Schuback HL, Arceci RJ, **Meshinchi S**: Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing. *Semin Hematol*. 2013 Oct;50(4):325-32. doi: 10.1053/j.seminhematol.2013.09.003.
79. Lee GE, Sung L, Fisher BT, Sullivan KE, McWilliams T, Tobias JW, **Meshinchi S**, Alonzo TA, Gamis A, Aplenc R: Gene Expression Profiling to Predict Viridans Group Streptococcal and Invasive Fungal Infection in Pediatric Acute Myeloid Leukemia: A Brief Report from the Children's Oncology Group. *Acta Haematol*. 131(3):167-9, 2014. No abstract available.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

80. Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**: BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. *Pediatr Blood Cancer*: Apr;61(4):647-52, 2014. PMID: PMC4285339
81. Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**, Walter RB: High Expression of Suppressor of Cytokine Signaling-2 Predicts Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. *Leuk Lymphoma*: 55(12):2817-21, 2014. PMID: PMC4285350
82. Stirewalt D, Pogossova-Agadjanyan E, Tsuchiya K, Joaquin J, **Meshinchi S**: Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML. *Blood Cancer*.: 2;4:e208, 2014. PMID: PMC4042297.
83. Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, **Meshinchi S**: Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group. *Br J Haematol*.: 166(2): 254-9, 2014. PMID: PMC4079767
84. Walter RB, Laszlo GS, Lionberger JM, Pollard JA, Harrington KH, Gudgeon CJ, Othus M, Rafii S, **Meshinchi S**, Appelbaum FR, Bernstein ID: Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. *Leukemia*.: 28(10):1969-77, 2014. PMID: PMC4167978
85. Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, **Meshinchi S**: Co-expression of NUP98/NSD1 and FLT3/ITD in Acute Myeloid Leukemia leads to High-Risk of Induction Failure: a COG and SWOG Report. *Blood*: 124(15):2400-7, 2014. PMID: PMC4192751
86. Dvinge H, Ries RE, Ilagan JO, Stirewalt DL, **Meshinchi S**, Bradley RK (2014): Sample processing obscures cancer-specific alterations in leukemic transcriptomes. *Proc Natl Acad Sci USA*: 111(47): 16802-7, 2014. PMID: PMC4250124
87. Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, **Meshinchi S**, Loken MR, Razzouk BI: AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. *Cancer*: 120(16):2482-9, 2014. PMID: PMC4126862.
88. Gamis AS, Alonzo TA, **Meshinchi S**, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R: Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531. *J Clin Oncol*.: 20;32(27):3021-32, 2014 PMID: PMC4162498.
89. Tarlock T, Chang B, Cooper T, Gross T, Gupta S, Neudorf S, Adlard K, Ho P, McGoldrick S, Watt T, Templeman T, Sisler I, Garee A, Thomson B, Woolfrey A, Estey E, **Meshinchi S**, Pollard J: Sorafenib Treatment Following Hematopoietic Stem Cell Transplant in Pediatric FLT3/ITD Acute Myeloid Leukemia. *Pediatr Blood Cancer* (manuscript ID PBC-14-1043.R1).
90. Schechter T, Gassas A, Chen H, Pollard J, **Meshinchi S**, Zaidman I, Hitzler J, Abdelhaleem M, Ho R, Domm J, Woolfrey A, Frangoul H. The outcome of allogeneic hematopoietic cell transplantation

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia. *Biol Blood Marrow Transplant*. 2015 Jan;21(1):172-95. doi: 10.1016/j.bbmt.2014.08.008.

91. Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogossova-Agadjanyan EL, Radich JP, Willman CL, **Meshinchi S**, Stirewalt DL: Prognostic Significance of NPM1 Mutations in the Absence of FLT3-Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report. *J Clin Oncol*.: 33(10):1157-64, 2015. PMID: PMC4372852
92. Tarlock K, **Meshinchi S**: Pediatric acute myeloid leukemia: biology and therapeutic implications of genomic variants. *Pediatr Clin North Am*: Feb;62(1):75-93, 2015.
93. **Meshinchi S**: Allelic ratio: a marker of clonal dominance. *Blood*: 124(23):3341-2, 2014. PMID: 25431476.
94. Tarlock K, Johnson D, Cornell C, Parnell S, **Meshinchi S**, Baker KS, Englund JA: Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole. *Pediatr Blood Cancer*: 2014 Oct 18. doi: 10.1002/pbc.25283.
95. Paguirigan AL, Smith J, **Meshinchi S**, Carroll M, Maley C, Radich JP. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. *Sci Transl Med*.:1;7(281):281re2, 2015. PMID: PMC4405099
96. Hsu CH, Nguyen C, Yan C, Ries RE, Chen QR, Hu Y, Ostronoff F, Stirewalt DL, Komatsoulis G, Levy S, Meerzaman D, Meshinchi S. Transcriptome Profiling of Pediatric Core Binding Factor AML. *PLoS One*. 2015 Sep 23;10(9):e0138782. doi: 10.1371/journal.pone.0138782. eCollection 2015. PMID: PMC4580636.
97. Vujkovic M, Attiyeh EF, Ries RE, Horn M, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Gerbing RB, Hirsch B, Raimondi S, Gamis AS, **Meshinchi S**, Aplenc R. Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group. *Cancer Genet*. 2015 Jul-Aug;208(7-8):408-13. doi: 10.1016/j.cancer.2015.04.010. PMID: PMC4523450.
98. Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**, Walter RB. Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. *Clin Cancer Res*. 2015 Jul 15;21(14):3187-95. doi: 10.1158/1078-0432.CCR-14-2684. Epub 2015 Mar 30. PMID: PMC4506237.
99. Kutny MA, Alonzo TA, Gamazon ER, Gerbing RB, Geraghty D, Lange B, Heerema NA, Sung L, Aplenc R, Franklin J, Raimondi SC, Hirsch BA, Konkashbaev A, Cox NJ, Onel K, Gamis AS, **Meshinchi S**. Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group. *Leukemia*. 2015 Dec;29(12):2424-6. doi: 10.1038/leu.2015.171. PMID: PMC4675677.
100. Kolb EA, **Meshinchi S**. Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies. *Hematology Am Soc Hematol Educ Program*. 2015 Dec 5;2015(1):507-13. doi: 10.1182/asheducation-2015.1.507.

Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.

101. Tarlock K, Alonzo TA, Gerbing R, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis A, **Meshinchi S**. Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group. *Clin Cancer Res*. 2015 Dec 7. pii: clincanres.1349.2015.
102. Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, **Meshinchi S**. CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. *J Clin Oncol*. 2016 Jan 19. pii: JCO626846.
103. Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**, Walter RB. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. *J Hematol Oncol*. 2015 Oct 20;8(1):115. doi: 10.1186/s13045-015-0215-4. PMCID: PMC4618184.
104. Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR, Alonzo TA, Guidry Auvil JM, Davidsen TM, Gesuwan P, Hermida L, Muzny DM, Dewal N, Rustagi N, Lewis LR, Gamis AS, Wheeler DA, Smith MA, Gerhard DS, **Meshinchi S**. Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse. *Cancer Res*. 2016 Mar 3.
105. de Rooij JD, Masetti R, van den Heuvel-Eibrink MM, Cayuela JM, Trka J, Reinhardt D, Rasche M, Sonneveld E, Alonzo TA, Fornerod M, Zimmermann M, Pigazzi M, Pieters R, **Meshinchi S**, Zwaan CM, Locatelli F. Recurrent genetic abnormalities can be used for risk-group stratification in pediatric AMKL: results of a retrospective intergroup study. *Blood*. 2016 Apr 25.
106. Brodersen LE, Alonzo TA, Menssen AJ, Gerbing RB, Pardo L, Voigt AP, Kahwash SB, Hirsch B, Raimondi S, Gamis AS, **Meshinchi S**, Loken MR. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. *Blood*. 2016 May 3.
107. Gerbing RB, Alonzo TA, Gamis AS, **Meshinchi S**, Plon SE, Bertuch AA, and Gramatges MM. Shorter remission telomere length predicts delayed neutrophil recovery after acute myeloid leukemia therapy: A report from the Children's Oncology Group. *J Clin Oncol*. 2016 Jun 27.
108. Laszlo GS, Harrington KH, Gudgeon CJ, Beddoe ME, Fitzgibbon MP, Ries RE, Lamba JK, McIntosh MW, **Meshinchi S**, Walter RB. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. *Oncotarget*. 2016 Jul 12.
109. Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**, Walter RB. Erratum to: High expression of myocyte enhancer factor 2c (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. *Journal of Hematology Oncology*. 2016 Nov 30.
110. Sung L, Aplenc R, Alonzo TA, Gerbing RB, Wang YC, **Meshinchi S** and Gamis AS. Association between Prolonged Neutropenia and Reduced Relapse Risk in Pediatric AML: A Report from the Children's Oncology Group. *International Journal of Cancer*. 2016 Nov 1.
111. Voight AP, Eidenschink Brodersen L, Pardo L, **Meshinchi S**, Loken MR. Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines. *Cytometry A*. 2016 Nov.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

112. Loken MR, Voigt AP, Eidenschink Brodersen L, Fritschle W, Menssen AJ, **Meshinchi S**, Wells DA. Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals. *Cytometry A*. 216 Nov.
113. Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, **Meshinchi S**. miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. *Pediatric Blood Cancer*. 2016 Dec.
114. Brown FC, Cifani P, Drill E, He J, Still E, Zhong S, Balasubramanian S, Pavlick D, Yilmazel B, Knapp KM, Alonzo TA, **Meshinchi S**, Stone RM, Kornblau SM, Marcucci G, Gamis AS, Byrd JC, Gonen M, Levine RL, Kentsis A. Genomics of primary chemoresistance and remission induction failure in pediatric and adult acute leukemia. *British Journal of Hematology*. 2017 Jan.
115. Maxson JE, Ries R, Wang YC, Gerbing RB, Kolb A, Thompson SL, Guidry Auvil JM, Marra, Ma Y, Zong S, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, Hermida LC, Farrar JE, Radich JP, Smith MA, Gerhard DS, Gamis AS, Alonzo TA, and **Meshinchi S**. CSF3R Mutations Represent a Novel Therapeutic Target in Pediatric AML with a High Degree of Overlap with CEBPA Mutations: a Report from COG AAML0531 and COG/NCI Target AML Initiative. *Blood*. 2017 Jan 5.
116. Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S, Spritz D, Ali S, Gay L, Erlich RL, Ross JS, Buxhaku J, Davies H, Faso V, Germain A, Glanville B, Miller VA, Stephens PJ, Janeway KA, Maris JM, **Meshinchi S**, Pugh TJ, Shern JF, Lipson D. Genomic profiling of a large set of diverse pediatric cancers identifies known and novel mutations across tumor spectra. *Cancer Research*. 2017 Jan 5.
117. Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, **Meshinchi S**, Gamis AS. Central nervous system disease in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. *Pediatric Blood Cancer*. 2017 April 28.
118. Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang YC, Gerbing RB, Sung L, Hirsch B, Raimondi S, Gamis AS, **Meshinchi S**, Aplenc R. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. *Blood*. 2017 Jun 8.
119. Qu X, Othus M, Davison J, Wu Y, Yan L, **Meshinchi S**, Ostronoff F, Estey EH, Radich JP, Erba HP, Appelbaum FR, Fang M. Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. *Cancer*. 2017 Jul 1.
120. Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials, AAML03P1 and AAML0531. *Blood*. 2017 Jul 3.
121. Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash SB, McKenney A, Kolb EA, Gamis AS, **Meshinchi S**. Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. *Clinical Cancer Research*. 2017 Jul 15. PMID: PMC5511553.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

122. Kutny MA, Alonzo TA, Gerbing RB, Wang YC, Raimondi SC, Hirsch BA, Fu CH, **Meshinchi S**, Gamis AS, Feusner JH, Gregory JJ Jr. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients with Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. *Journal of Clinical Oncology*. 2017 Aug 2.
123. Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, **Meshinchi S**. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in Do Novo Acute Myeloid Leukemia: Report from Randomized Phase III Children's Oncology Group Trial AAML0531. *Journal of Clinical Oncology*. 2017 Aug 10.
124. Appelbaum FR, **Meshinchi S**. Measure for Measure: Measuring the Impact of Measuring Residual Disease in Acute Myeloid Leukemia. *Journal of Oncology Practice*. 2017 Aug.
125. Voigt AP, Eidenschink Brodersen L, Alonzo TA, Gerbing RB, Menssen AJ, Wilson ER, Kahwash S, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**, Wells DA, Loken MR. Phenotype in Combination with Genotype Improves Outcome Prediction in Acute Myeloid Leukemia: A Report from Children's Oncology Group Protocol AAML0531. *Hematologica*. 2017 Sept 7. PMID: PMC5709105.
126. Degnin M, Agarwal A, Tarlock K, **Meshinchi S**, Drucker BJ, Tognon CE. Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens. *Journal of Pediatric Hematology Oncology*. 2017 Oct.
127. Lim EL, Trinh DL, Ries RE, Wang J, Gerbing RB, Ma Y, Topham J, Hughes M, Pleasance E, Mungall AJ, Moore R, Zhao Y, Aplenc R, Sung L, Kolb EA, Gamis A, Smith M, Gerhard DS, Arceci RJ, Alonzo TA, **Meshinchi S**, **Marra MA**. MicroRNA Expression-based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. *Journal of Clinical Oncology*. Epub. 2017 Oct. PMID: PMC5721230.
128. Bolouri H, Farrar JE, Triche Jr T, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall A, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Guidry Auvil JM, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, **Meshinchi S**. Comprehensive Characterization of Pediatric Acute Myeloid Leukemia Reveals Novel Molecular Features and Age-Specific Interactions. *Nature Medicine*. Nat Med. 2018 Jan;24(1):103-112. doi: 10.1038/nm.4439.
129. Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, **Meshinchi S**, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG. The genetic basis and cell of origin of mixed phenotype acute leukaemia. *Nature*. 2018 Oct;562(7727):373-379. doi: 10.1038/s41586-018-0436-0.
130. Noort S, Zimmermann M, Reinhardt D, Cuccuini W, Pigazzi M, Smith J, Ries RE, Alonzo TA, Hirsch B, Tomizawa D, Locatelli F, Gruber TA, Raimondi S, Sonneveld E, Cheuk DK, Dworzak M, Stary J, Abrahamsson J, Arad-Cohen N, Czogala M, De Moerloose B, Hasle H, **Meshinchi S**,

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- van den Heuvel-Eibrink M, Zwaan CM. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. *Blood*. 2018 Oct 11;132(15):1584-1592. doi: 10.1182/blood-2018-05-849059.
131. Gbadamosi M, **Meshinchi S**, Lamba JK. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia. *Future Oncol*. 2018 Dec;14(30):3199-3213. doi: 10.2217/fon-2018-0325.
132. Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, **Meshinchi S**, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JM, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. *Biol Blood Marrow Transplant*. 2018 Oct;24(10):2040-2046. doi: 10.1016/j.bbmt.2018.06.010.
133. Stockard B, Garrett T, Guingab-Cagmat J, **Meshinchi S**, Lamba J. Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia. *Sci Rep*. 2018 Apr 3;8(1):5534. doi: 10.1038/s41598-018-23863-9.
134. *Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y, Rusch MC, Easton J, Huether R, Gonzalez-Pena V, Wilkinson MR, Hermida LC, Davis S, Sioson E, Pounds S, Cao X, Ries RE, Wang Z, Chen X, Dong L, Diskin SJ, Smith MA, Guidry Auvil JM, Meltzer PS, Lau CC, Perlman EJ, Maris JM, **Meshinchi S**, Hunger SP, Gerhard DS, Zhang J. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. *Nature*. 2018 Mar 15;555(7696):371-376. doi: 10.1038/nature25795.
135. Sarthy J, Zha J, Babushok D, Shenoy A, Fan JM, Wertheim G, Himebauch A, Munchel A, Taraseviciute A, Yang S, Shima H, Narumi S, **Meshinchi S**, Olson TS. Poor outcome with hematopoietic stem cell transplantation for bone marrow failure and MDS with severe MIRAGE syndrome phenotype. *Blood Adv*. 2018 Jan 23;2(2):120-125. doi: 10.1182/bloodadvances.2017012682.
136. Lamba JK, Voigt AP, Chauhan L, Shin M, Aplenc R, Eidenschink Brodersen L, Gamis AS, **Meshinchi S**, Loken MR. CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients. *Leuk Lymphoma*. 2018 Sep;59(9):2250-2253. doi: 10.1080/10428194.2017.1421756.
137. Tarlock K, Zhong S, He Y, Ries R, Severson E, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto GA, Vergillo JA, Kolb EA, Ross JS, Mughal T, Stephens PJ, Miller V, ****Meshinchi S, **He J**. Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. *Oncotarget*. 2018 May 29;9(41):26417-26430. doi: 10.18632/oncotarget.25443. eCollection 2018 May 29.
138. Nagarajan R, Gerbing R, Alonzo T, Johnston DL, Aplenc R, Kolb EA, **Meshinchi S**, Barakat LP, Sung L. Quality of life in pediatric acute myeloid leukemia: Report from the Children's Oncology Group. *Cancer Med*. Epub 2019 Jun 12. doi: 10.1002/cam4.2337.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

139. Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries RE, Hylkema T, Joaquin J, Sarukkai L, Raimondi S, Hirsch BA, Sung L, Aplenc R, Bernstein ID, Gamis AS, ****Meshinchi S, **Pollard JA**, Loken MR, Pardo L. Functional Properties of KIT Mutations are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia. *Clin Cancer Res*. Epub 2019 Jun 10. pii: clincanres.1897.2018. doi: 10.1158/1078-0432.CCR-18-1897.
140. Rafiee R, Chauhan L, Alonzo TA, Wang YC, Elmasry A, Loken MR, Pollard J, Aplenc R, Raimondi S, Hirsch BA, Bernstein ID, Gamis AS, **Meshinchi S**, Lamba JK. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial. *Blood Cancer J*. Epub 2019 May 21;9(6):51. doi: 10.1038/s41408-019-0211-y.
141. *Jacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D'Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, **Meshinchi S**, Haferlach T, Mullighan CG. Genomic subtyping and therapeutic targeting of acute erythroleukemia. *Nat Genet*. 2019 Apr;51(4):694-704. doi: 10.1038/s41588-019-0375-1.
142. *McNeer NA, Philip J, Geiger H, Ries RE, Lavallée VP, Walsh M, Shah M, Arora K, Emde AK, Robine N, Alonzo TA, Kolb EA, Gamis AS, Smith M, Gerhard DS, Guidry-Auvil J, **Meshinchi S**, Kentsis A. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. *Leukemia*. Epub 2019 Aug;33(8):1934-1943. doi: 10.1038/s41375-019-0402-3.
143. Papageorgiou I, Loken MR, Brodersen LE, Gbadamosi M, Uy GL, **Meshinchi S**, Lamba JK. CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents. *Leuk Lymphoma*. Epub 2019 Feb 5:1-4. doi: 10.1080/10428194.2019.1569232.
144. Dahlberg A, Leisenring W, Bleakley M, **Meshinchi S**, Baker KS, Summers C, Hadland B, Delaney C, Mallhi K, Burroughs L, Carpenter P, Woolfrey A. Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children. *Bone Marrow Transplant*. Epub 2019 Jan 22. doi: 10.1038/s41409-019-0438-z.
145. *Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, **Meshinchi S**. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. *Nat Med*. 2018 Jan;24(1):103-112. doi: 10.1038/nm.4439. Epub 2017 Dec 11. Erratum in: *Nat Med*. 2018 Apr 10;24(4):526. *Nat Med*. 2019 Mar;25(3):530.
146. McNeil MJ, Parisi MT, Hijjiya N, **Meshinchi S**, Cooper T, Tarlock K. Clinical and Radiographic Response of Extramedullary Leukemia in Patients Treated With Gemtuzumab Ozogamicin. *J Pediatr Hematol Oncol*. 2019 Apr;41(3):e174-e176. doi: 10.1097/MPH.0000000000001201.
147. Pardo LM, Voigt AP, Alonzo TA, Wilson ER, Gerbing RB, Paine DJ, Dai F, Menssen AJ, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**, Wells DA, Brodersen LE, Loken MR. Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- from the Children's Oncology Group. *Cytometry B Clin Cytom.* 2019 Jul 11. doi: 10.1002/cyto.b.21829.
148. Hagiwara K, Ding L, Edmonson MN, Rice SV, Newman S, Easton J, Dai J, **Meshinchi S**, Ries RE, Rusch M, Zhang J. RNAIndel: discovering somatic coding indels from tumor RNA-Seq data. *Bioinformatics.* 2019 Oct 8. pii: btz753. doi: 10.1093/bioinformatics/btz753.
 149. Braun T, Okhovat M, Coblentz C, Carratt S, Foley A, Schonrock Z, Smith B, Nevenon K, Davis B, Garcia B, LaTocha D, Weeder B, Grzadkowski M, Estabrook J, Manning H, Watanabe-Smith K, Smith J, Leonti A, Ries R, Jeng S, McWeeney S, Di Genua C, Drissen R, Nerlov C, **Meshinchi S**, Carbone L, Druker B, Maxson J. Myeloid Lineage Enhancers Drive Oncogene Synergy in CEBPA/CSF3R Mutant Acute Myeloid Leukemia. *Nature.* 2019 Nov 29;10(1):5455. doi: 10.1038/s41467-019-13364-2.
 150. Noort S, Wander P, Alonzo TA, Smith J, Ries RE, Gerbing RB, Dolman MEM, Locatelli F, Reinhardt D, Baruchel A, Stary J, Molenaar JJ, Stam RW, van den Heuvel-Eibrink MM, Zwaan M, **Meshinchi S**. The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia. *Haematologica.* 2020 May 7. pii: haematol.2019.236745. doi: 10.3324/haematol.2019.236745. [Epub ahead of print]
 151. Le Q, Hadland B, **Meshinchi S**, Bernstein I. Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatment. *Leukemia.* 2020 Jun 8. doi: 10.1038/s41375-020-0893-y. Online ahead of print.
 152. *Smith JL, Ries RE, Hylkema T, Alonzo TA, Gerbing RB, Santaguida MT, Eidenschink Brodersen L, Pardo L, Cummings CL, Loeb KR, Le Q, Imren S, Leonti AR, Gamis AS, Aplenc R, Kolb EA, Farrar JE, Triche TJ Jr, Nguyen C, Meerzaman D, Loken MR, Oehler VG, Bolouri H, **Meshinchi S**. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study. *Clin Cancer Res.* 2020 Feb 1;26(3):726-737. doi: 10.1158/1078-0432.CCR-19-1800. Epub 2019 Nov 12.
 153. Davies SM, Iannone R, Alonzo TA, Wang YC, Gerbing R, Soni S, Kolb EA, **Meshinchi S**, Orchard PJ, Burns LJ, Shenoy S, Leung W. A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. *Biol Blood Marrow Transplant.* 2020 Apr;26(4):712-717. doi: 10.1016/j.bbmt.2019.12.723. Epub 2019 Dec 21.
 154. Tarlock K, Alonzo T, Wang YC, Gerbing RB, Ries RE, Hylkema T, Smith JL, Maxson JE, **Meshinchi S**. Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia. *Blood.* 2020 Apr 30;135(18):1603-1606. doi: 10.1182/blood.2019004179. PMID: 32187354; PMCID: PMC7193184.
 155. Aplenc R, **Meshinchi S**, Sung L, Alonzo T, Choi J, Fisher B, Gerbing R, Hirsch B, Horton T, Kahwash S, Levine J, Loken M, Brodersen L, Pollard J, Raimondi S, Kolb EA, Gamis A. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. *Haematologica.* 2020 Jul;105(7):1879-1886. doi: 10.3324/haematol.2019.220962. Epub 2020 Feb 6.
 156. Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Jenkins IC, Fang M, Huynh M, Kopecky KJ, List AF, Naru J, Radich JP, Stevens E, Willborg BE, Willman CL, Wood BL, Zhang Q, **Meshinchi S**, Stirewalt DL. AML risk

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. *Biomark Res.* 2020 Aug 12;8:29. doi: 10.1186/s40364-020-00208-1. eCollection 2020.
157. Biernacki MA, Foster KA, Woodward KB, Coon ME, Cummings C, Cunningham TM, Dossa RG, Brault M, Stokke J, Olsen TM, Gardner K, Estey E, **Meshinchi S**, Rongvaux A, Bleakley M. CBFβ-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. *J Clin Invest.* 2020 Aug 24:137723. doi: 10.1172/JCI137723. Online ahead of print.
158. Hoff FW, van Dijk AD, Qiu YH, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo T, **Meshinchi S**, De Bont E, Bruggeman SW, Kornblau SM, Horton TM. Heat Shock Factor 1 (HSF1-pSer326) Predicts Response to Bortezomib-Containing Chemotherapy in Pediatric AML: A COG Study. *Blood.* 2020 Sep 21:blood.2020005208. doi: 10.1182/blood.2020005208. Epub ahead of print. PMID: 32959058.
159. Brodersen LE, Gerbing RB, Pardo ML, Alonzo TA, Paine D, Fritschle W, Hsu FC, Pollard JA, Aplenc R, Kahwash SB, Hirsch B, Ramondi S, Wells D, Kolb EA, Gamis AS, Meshinchi S, Loken MR. Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report. *Blood Adv.* 2020 Oct 27;4(20):5050-5061. doi: 10.1182/bloodadvances.2020002070. PMID: 33080007; PMCID: PMC7594384.
160. Chisholm KM, Heerema-McKenney AE, Choi JK, Smith J, Ries RE, Hirsch BA, Raimondi SC, Alonzo TA, Wang YC, Aplenc R, Sung L, Gamis AS, Meshinchi S, Kahwash SB. Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group. *Blood Adv.* 2020 Dec 8;4(23):6000-6008. doi: 10.1182/bloodadvances.2020002712. PMID: 33284945; PMCID: PMC7724911.
161. Gbadamosi MO, Shastri VM, Hylkema T, Papageorgiou I, Pardo L, Cogle CR, Doty A, Loken MR, Meshinchi S, Lamba JK. Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms. *Future Oncol.* 2021 Jan;17(3):263-277. doi: 10.2217/fon-2020-0746. Epub 2020 Dec 24. PMID: 33356566.
162. Milan T, Celton M, Lagacé K, Roques É, Safa-Tahar-Henni S, Bresson E, Bergeron A, Hebert J, Meshinchi S, Cellot S, Barabé F, Wilhelm BT. Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis. *Haematologica.* 2020 Dec 30; Online ahead of print. doi: 10.3324/haematol.2020.271619. PMID: 33375773.
163. McLeod C, Gout AM, Zhou X, Thrasher A, Rahbarinia D, Brady SW, Macias M, Birch K, Finkelstein D, Sunny J, Mudunuri R, Orr BA, Treadway M, Davidson B, Ard TK, Chiao A, Swistak A, Wiggins S, Foy S, Wang J, Sioson E, Wang S, Michael JR, Liu Y, Ma X, Patel A, Edmonson MN, Wilkinson MR, Frantz AM, Chang TC, Tian L, Lei S, Islam SMA, Meyer C, Thangaraj N, Tater P, Kandali V, Ma S, Nguyen T, Serang OA, McGuire I, Robison N, Gentry D, Tang X, Palmer LE, Wu G, Suh E, Tanner L, McMurry J, Lear M, Pappo AS, Wang Z, Wilson CL, Cheng Y, Meshinchi S, Alexandrov LB, Weiss MJ, Armstrong GT, Robison LL, Yasui Y, Nichols KE, Ellison DW, Bangur C, Mullighan CG, Baker SJ, Dyer MA, Miller G, Newman S, Rusch M, Daly R, Perry K, Downing JR, Zhang J. St. Jude Cloud-a Pediatric Cancer Genomic Data Sharing Ecosystem. *Cancer Discov.* 2021 Jan 6:CD-20-1230. doi: 10.1158/2159-8290.CD-20-1230. Epub ahead of print. PMID: 33408242.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

Book Chapters and Reviews: **Authors contributed equally to the manuscript

1. Sanchez ER, Tienrungrroj W, **Meshinchi S**, Bresnick EH, Pratt WB: “Inhibition of glucocorticoid receptor conversion to the DNA-binding state and inhibition of subunit dissociation“ in Sterol/Steroid Hormone Action, T. Spelsberg and R. Kumar (eds.). Boston: Martinus Nijhoff. 1987, 195-211.
2. Pratt WB, Sanchez ER, Bresnick EH, **Meshinchi S**, Scherrer LC, Dalman FC, Welsh MJ: “Interaction of the glucocorticoid receptor with the Mr 90,000 heat shock protein: An evolving model of ligand-mediated receptor transformation and translocation”. *Cancer Res.* (Suppl) 49:2222s-2229s, 1989.
3. Pratt WB, Redmond T, Sanchez ER, Bresnick EH, **Meshinchi S**, Welsh MJ: “Speculations on the role of the 90-kDa heat shock protein in glucocorticoid receptor transport and function” in The Steroid/Thyroid Hormone Receptor Family and Gene Regulation, J. Carlstedt-Duke, H. Erickson, JA Gustafsson (eds.). Basel: Birkhauser-Verlag, 1989, 109-126.
4. Stirewalt DL, **Meshinchi S**, and Radich JP. Molecular targets in AML. *Blood Rev.* 2003 Mar; 17(1):15-23.
5. **Zwaan CM, ****Meshinchi S**, Radich JP, Veerman AJP, Huisman DR, Munske L, Podleschny M, Hählen K , Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJL, Griesinger F. “FLT3 Internal Tandem Duplication in childhood acute myeloid leukemia (AML): prognostic significance and relation to cellular drug resistance” in Towards subgroup-directed therapy in acute myeloid leukemia, Krips, Meppel, Netherlands, 2003, 101-115.
6. **Meshinchi S**, Smith FO, and Arceci RJ. “Prognostic factors in pediatric acute myeloid leukemia”. *Curr Oncol Rep.* 2003 Nov;5(6):489-497.
7. **Meshinchi S**, Alonzo TA, Lange BJ, Smith FO and Arceci RJ. “The use of prognostic factors in directing risk-based therapy and the development of new therapeutic approaches in childhood AML: Proceedings of international symposium on childhood MDS and AML.” Annals of Hematology (Supple), Springer-Verlag, Germany, January 2006, 52-54.
8. Stirewalt DL and **Meshinchi S**. “Tyrosine kinase alterations in AML,” in Molecular Oncology: Causes of Cancer and Targets for Treatment, E. Gelmann, C. Sawyers, and F. Rauscher III (eds.), Cambridge University Press, New York, 2008.
9. Stirewalt DL and **Meshinchi S**. “Receptor Tyrosine Kinase Alterations in AML – Biology and Therapy,” in Acute Myelogenous Leukemia: Genetics, Biology and Therapy, ST Rosen (ed.), 2009, 85-108.
10. Radhi M, **Meshinchi S**, Gamis S: Prognostic Factors in Pediatric AML. *Curr Hematol Malig Rep:* 5(4): 200-6, 2010. PMID: 20652454. Review. Radhi M, **Meshinchi S**, Gamis S: Prognostic Factors in Pediatric AML. *Curr Hematol Malig Rep:* 5(4): 200-6, 2010. PMID: 20652454. Review.
11. Stirewalt DL, Meshinchi S: Receptor tyrosine kinase alterations in AML - biology and therapy. *Cancer Treat Res.* 2010;145:85-108. Review.
12. **Meshinchi S**, Weinstein HJ, Arceci RJ. “Myeloid Malignancies”, in the 22nd Edition of Rudolph’s Pediatrics, Rudolph AM, Rudolph C, First L, Lister G, Gershon AA (eds.), 2011.
13. Arceci RJ, **Meshinchi S**. “Biology of Acute Myeloid Leukemia”, in Childhood Leukemia, Reaman GH, Smith FO (eds.), 2011, 63-76

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

14. Mullighan CG, Hunger SP, **Meshinchi S**. “Molecular Genetics in Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia”, in Hematological Malignancies in Children, Adolescents and Young Adults, Cairo MS, Perkins S (eds.), Singapore: World Scientific. 2012, 121-142.
15. Arceci RJ, **Meshinchi S**, Rosenblat TL, Jurcic JG, Tallman MS. “Childhood, Adolescent and Young Adult (CAYA) Acute Myeloid Leukemias”, in Hematological Malignancies in Children, Adolescents and Young Adults, Cairo MS, Perkins S (eds.), Singapore: World Scientific. 2012, 237-266.
16. Carpenter PA, **Meshinchi S**, Davis SM: Transplantation for AML in Children. *Biol Blood Marrow Transplant* 18: S33-9, 2012. PMID: 22226110. Review.
17. Pulsipher MA, McManus M, **Meshinchi S**. “Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia,” in Thomas’ Hematopoietic Cell Transplantation, Appelbaum FR, Forman SJ, Negrin RS, and Antin JH (eds.). ISBN: 978-1-118-41600-6 December 2016 Wiley-Blackwell, 576-587.
18. Gamis AS, Alonzo TA, Perentesis JP, **Meshinchi S**; on behalf of the COG Acute Myeloid Leukemia Committee. Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia. *Pediatr Blood Cancer* 60: 964-71, 2013. PMID: 23255301. Review.
19. **Meshinchi S** and Stirewalt DL. “FMS-related tyrosine kinase 3,” in Molecular Oncology: Causes of Cancer and Targets for Treatment, Gelmann EP, Sawyers CL, and Rauscher FJ (eds.), 2014, 144-161.
20. Horan J, Hasle H, Meshinchi S. “Acute Myeloid Leukemia,” in Hematopoietic Cell Transplantation in Children with Cancer, Smith FO, Reaman GH, and Racadio JM (eds.), Heidelberg, Springer, 2014.
21. Arceci RJ, Berman JN, **Meshinchi S**. “Acute Myeloid Leukemia,” in Cancer Genomics: From Bench to Personalized Medicine, Dellaire G, Berman JN, and Arceci RJ (eds.), Amsterdam, Academic, 2014.
22. Arceci RJ, **Meshinchi S**. “Acute Myeloid Leukemia and Myelodysplastic Syndromes” in Principles and Practice of Pediatric Oncology, Pizzo PA & Poppo DG (eds.). (2016). Principles and Practice of Pediatric Oncology. (7th Edition). Philadelphia: Wolters Kluwer. 20: 498-544.
23. Aplenc R, **Meshinchi S**. “Acute Myeloid Leukemia and Myelodysplastic Syndromes” in Principles and Practice of Pediatric Oncology, 8th Edition, Pizzo P, and Poppo D (eds.), Philadelphia, Wolters Kluwer, 2019. In press.

Abstracts (from 2008 to present):

1. Zeng R and **Meshinchi S**. Single Cell Molecular Genotyping Reveals Significant Molecular Heterogeneity at Diagnosis and Emergence of Clonal Dominance at Relapse Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2944. Presenter: RZ
2. Franklin J, Alonzo T, Hurwitz C, Gerbing R, Smith F, Arceci R, Feusner J, Mathew P, Iannone R, **Meshinchi S**, Lavey R, Wallace J, Anderson K, Winter L, Glick K, Hirsch B, Raimondi S, and Gamis A. COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML) Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 136. Presenter: JF

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

3. Ho PA, Alonzo TA, Gerbing RB, Pollard J, Stirewalt DL, Hurwitz C, Heerema NA, Lange B, Raimondi S, Franklin J, Radich J, **Meshinchi S**. CEBPA Mutations Predict Favorable Prognosis in Pediatric AML Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 142. Presenter: PH
4. Pollard J, Zeng R, Ho PA, Alonzo TA, Gerbing RB, Stirewalt DL, Hurwitz C, Heerema NA, Lange B, Raimondi S, Franklin J, Radich J, **Meshinchi S** Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML A: Report from Children's Oncology Group Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 143. Presenter: JP
5. Brown B, Alonzo TA, Gerbing RB, McIntyre E, Lange B, Small D, and **Meshinchi S** High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children's Oncology Group Study, Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 147. Presenter: BB
6. Pollard J, Alonzo TA, Gerbing RB, Stirewalt DL, Raimondi S, Franklin J, Gamis A, Loken R, and **Meshinchi S** Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 148. Presenter: JP
7. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Ries RE, Gerbing RB, Fan W, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Zhao LP, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, and **Meshinchi S**: Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a Children's Oncology Group and Southwest Oncology Group Study. Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: PH
8. Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL, Heerema NA, Raimondi SC, Hirsch B, Franklin JL, Lange B, Gamis AS, Alonzo TA, and **Meshinchi S**: The WT1 synonymous SNP rs16754 is associated with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric AML: a report from the Children's Oncology Group Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: PH
9. Kutny MA, Moser BK, Gregory J, Woods WG, Feusner JH, **Meshinchi S**: FLT3 Mutation are Prevalent and are significantly associated with Induction Death in Pediatric Acute Promyelocytic Leukemia Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: MK
10. Kutny MA, Alonzo TA, Gerbing RB, Ho P, Daniel Geraghty D, Lange B, Heerema NA, and **Meshinchi S**: TET2 SNP rs2454206 (I1762V) Correlates with Improved Survival in Pediatric Acute Myelogenous Leukemia, a Report from the Children's Oncology Group Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: MK
11. Kutny MA, Miller K, Alonzo TA, Gerbing RB, Ho P, Gamis AS, Raimondi SC, Hirsch BA, and **Meshinchi S**: CBL Mutations in Pediatric Acute Myelogenous Leukemia are a Rare Event, a Report from the Children's Oncology Group Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: MK
12. Kutny MA, Collins S, Loeb K, Walter R, and **Meshinchi S**: All trans retinoic acid (ATRA) causes extensive differentiation in NPM mutant, non-APL leukemic cell line OCI-AML3. Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: MK
13. Alonzo TA, Ho PA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, Cooper T, Franklin JL, Laura Pardo L, Loken M, and **Meshinchi S**: Conventional Cytogenetics, Molecular Profiling, and Flow Cytometric Response Data Allow the Creation of a Two-Tiered Risk-Group System for Risk-

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

based Therapy Allocation in Childhood AML – a Report from the Children’s Oncology Group Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: TA

14. **Meshinchi S**, Alonzo T, Gerbing R, Ho P, Gamis A, Raimondi S, Hirsch B, Cooper T, Franklin J, Pardo L, Loken M: Identification of postinduction minimal residual disease by multidimensional flow cytometry identifies patients with AML at high risk of relapse and poor outcome – a report from the Children’s Oncology Group Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: SM
15. Walter RB, Gudgeon CJ, Ries RE, Alonzo TA, Gerbing RB, Ho PA, Gamis AS, Raimondi SC, Hirsch BA, Franklin JL, and **Meshinchi S**: High Expression Of Neutrophil Elastase Predicts For Improved Survival In Pediatric Acute Myeloid Leukemia (AML): A Report From The Children’s Oncology Group Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: RW
16. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Galer C, Zeng R, Miller KL, Kuhn J, Raimondi SC, Hirsch B, Franklin JL, Gamis A, Loken M, and **Meshinchi S**: Correlation of CD33 Expression Level with Disease Risk Group Classification and Induction Response in Pediatric AML: A Report from the Children’s Oncology Group Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: JP
17. Hughes MD, Zeng R, Miller K, and **Meshinchi S**: Augmentation of sensitivity of FLT3/ITD assay allows detection of minimal residual disease in stem cell transplant recipients – correlation with flow cytometric MRD assessment. Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: MH
18. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Burden L, Wallas T, Davies SM, Smith FO, **Meshinchi S**, Gamis AS: Flow Cytometric Assessment Of Post Induction Response In Patients With Sub-Optimal Morphologic Response To Induction Chemotherapy – A Report From The Children’s Oncology Group AML Protocol AAML0531 Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: ML
19. Walter RB, Pollard J, Harrington K, **Meshinchi S**, and Bernstein I: Sequential Acquisition of Somatic Mutations in Progenitors with Different Proliferative and Repopulation Potential in Human Acute Myeloid Leukemia Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: RW
20. Pogossova-Agadjanyan EL, Kopecky KJ, Lee H, Godwin J, List A, Anderson J, Petersdorf S, Willman C, **Meshinchi S**, Radich JP, and Stirewalt DL: Over-expression of Novel IRF8 Splice Variants is Associated with a Significant Decrease in Relapse-Free Survival in adult AML Patients. Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: EP
21. Pogossova-Agadjanyan EL, Lee H, Kepler C, **Meshinchi S**, Radich JP, and Stirewalt DL: Methylation Regulates Expression of Novel Splice Variant and Wild Type Transcripts of IRF8. Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: EP
22. Lacayo NJ, Cohen A, Westfall M, Lackey A, Xin X, Gayko U, Putta S, **Meshinchi S**, Raimondi SC, Alonzo TA, Arceci RJ, Ravindranath Y, Van Houten Dahl G, and Cesano A: Single-cell network profiling (SCNP) signatures predict response to induction therapy and relapse risk in pediatric patients with acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: NL
23. Sung L, Alonzo TA, Gerbing R, Aplenc R, **Meshinchi S**, Burden L, Raimondi S, Hirsch B, Kahwash S, McKenney A, Winter L, Glick K, Byron P, Wallas T, Smith F, and Gamis A: High

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- Mortality in Hyperleukocytosis in Pediatric Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: LS
24. Sung L, Aplenc R, Alonzo TA, Gerbing RB, **Meshinchi S**, Burden L, Raimondi S, Hirsch B, Kahwash S, McKenney A, Winter L, Glick K, Byron P, Wallas T, Smith FO, and Gamis A: Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report from the Children's Oncology Group. Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: LS
 25. Gamis AS, Alonzo TA, Gerbing RB, Aplenc R, Sung L, **Meshinchi S**, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Burden L, Wallas T, Davies SM, and Smith FO: Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531. Blood (ASH Annual Meeting Abstracts), Dec 2010. Presenter: AG
 26. Ostronoff F, Othus M, Ho PA, Petersdorf SH, Anderson JE, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, **Meshinchi S**: KIT Mutations are Rare Among Elderly AML Patients: A SWOG Report. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 2510. Presenter: FO
 27. Ho PA, Alonzo TA, Gerbing RB, Kuhn J, Pollard JA, Hirsch BA, Raimondi SC, Gamis AS, **Meshinchi S**: The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 rs16754 Status: A Report from the Children's Oncology Group (COG). Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 1444. Presenter: PH
 28. Pogossova-Agadjanyan EL, **Meshinchi S**, Lee H, Wood BL, Stirewalt DL: Expression Differences of Prognostic Biomarkers in Mononuclear Cells (MNCs) and Malignant Blasts of Acute Myeloid Leukemia (AML) Patients. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 1468. Presenter: EP
 29. Kutny MA, Alonzo TA, Gerbing RB, Geraghty D, Gamis AS, Lange B, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, **Meshinchi S**: TET2 Mutations are Associated with Poor Outcome in Pediatric AML: A Report from the Children's Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 569. Presenter: MK
 30. Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange B, Twardy DJ, **Meshinchi S**: FACS Analysis of Stat3/5 Signaling Reveals Ligand Sensitivity as a Significant Prognostic Factor in Pediatric AML: A Children's Oncology Group Report. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 938. Presenter: MR
 31. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Fransisco L, Wallas T, Davies SM, Smith FO, Gamis AS, **Meshinchi S**: Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report from the Children's Oncology Group AML Protocol AAML0531. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 939. Presenter: ML
 32. Lamba J, Mortland LJ, Mitra A, Walter RB, Pollard JA, Alonzo TA, Gerbing RB, Hirsch BA, Raimondi SC, Franklin J, **Meshinchi S**: Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- with Gemtuzumab Ozogamicin-Containing Chemotherapy. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 3489. Presenter: JL
33. Ho PA, Othus M, Ostronoff F, Petersdorf SH, Anderson JE, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, **Meshinchi S**: Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report from SWOG. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 3516. Presenter: PH
 34. Ostronoff F, Othus M, Ho PA, Petersdorf SH, Anderson JE, Godwin JE, Willman CL, Radich JP, Appelbaum FR, Stirewalt DL, **Meshinchi S**: DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 3519. Presenter: FO
 35. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKeeney A, Winter L, Glick K, Byron P, Fransisco L, Wallas T, Davies SM, Smith FO, Gams AS, **Meshinchi S**: Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML at High Risk of Relapse – a Report from the Children’s Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 3545. Presenter: ML
 36. Moore AS, Alonzo TA, Gerbing RB, Lange B, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gams AS, **Meshinchi S**: The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report from the Children’s Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 3555. Presenter: AM
 37. Lacayo NJ, Alonzo TA, Gayko U, Westfall M, Purvis N, Putta S, Hackett J, Cohen AC, Gerbing RB, Dahl GV, Gams AS, **Meshinchi S**: Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): A Validation Study Results. Blood (ASH Annual Meeting Abstracts), Nov 2011, 118: 3544. Presenter: NL
 38. Bolouri H, Ries RE, Ramamurthy R, Alonzo TA, Guidry Auvil JM, Davidsen TM, Gesuwan P, Gams AS, Smith MA, Gerhard DS, Arceci RJ, **Meshinchi S**: Integrative Network Analysis of Pediatric AML Whole Genomes, cDNA Expression and Clinical Data Elements Reveals Shared As Well As t(8;21), Inv16 and MLL Specific Pathways; A Report from COG/NCI Target AML Initiative. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 3519. Presenter: HB
 39. Kutny MA, Alonzo TA, Gerbing RB, Franklin J, Raimondi SC, Hirsch BA, Gams AS, **Meshinchi S**: Expression of RUNX1 and RUNX1T1 Correlates with Cytogenetic Subgroups in Pediatric AML: A Report From the Children’s Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120:1425. Presenter: MK
 40. Helton HL, Ries RE, Alonzo TA, Gerbing RB, Trevino LR, Farrar J, Guidry Auvil JM, Davidsen TM, Gesuwan P, Muzny DM, Gams AS, Franklin J, Wheeler DA, Smith MA, Gerhard DS, Arceci RJ, **Meshinchi S**: Clinically Significant Mutations, Deletions and Translocations Involving ETV6 Identified by Whole Genome and Whole Exome Sequencing; Report From NCI/COG Target AML Initiative. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 125. Presenter: HH
 41. **Meshinchi S**, Ries RE, Trevino LR, Hampton OA, Alonzo T, Farrar JE, Guidry Auvil JM, Davidsen TM, Gesuwan P, Muzny DM, Gams AS, Helton HL, Wheeler DA, Smith MA, Gerhard DS, Arceci RJ: Identification of Novel Somatic Mutations, Regions of Recurrent Loss of

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing – an NCI/COG Target AML Study. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 123. Presenter: SM
42. Gore L, Macy ME, Mechinaud F, Narendran A, Alvaro F, Arndt CAS, Barnette P, Boklan J, Cooper T, Martin L, Tchong W, Tarasoff P, Jones MM, **Meshinchi S**, Arceci RJ: Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML). Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 1517. Presenter: LG
 43. Ramamurthy R, Alonzo TA, Gerbing RB, Loken MR, Pardo L, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Francisco LE, Lavey RS, Davies SM, Smith FO, Gamis AS, **Meshinchi S**: Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120:2388. Presenter: RR
 44. Ho PA, Alonzo T, Gerbing RB, Pollard JA, Raimondi SC, Hirsch BA, Cooper T, Gamis AS, **Meshinchi S**: High *EVII* expression Is Associated with *MLL* rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 2530. Presenter: PH
 45. Palomo Moraleda P, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, **Meshinchi S**: Acute Myeloid Leukemia with t(6;9)(p23;q34) Is Associated Poor Outcome in Childhood AML Regardless of FLT3/ITD Status, A Report From Children's Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 2541. Presenter: PPM
 46. Stirewalt DL, Alonzo TA, Pogossova-Agadjanyan EL, Gerbing RB, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**: Novel IL23R Splice Variant Is Associated with Worse Prognosis in Pediatric Patients with AML. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 2546. Presenter: DS
 47. Stirewalt DL, Alonzo TA, Pogossova-Agadjanyan EL, Gerbing RB, Franklin J, Lee H, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**: Novel IRF8 Splice Variants Are Validated As a New Prognostic Biomarker for Adverse Outcome in an Independent Population of Pediatric Patients with AML. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 2550. Presenter: DS
 48. Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Raimondi SC, Hirsch BA, Franklin J, Gamis AS, **Meshinchi S**: Elevated *BAALC* Gene Expression Lacks Clinical Significance in Pediatric AML- A Report From the Children's Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 2553. Presenter: JP
 49. Ostronoff F, Othus M, Kantarjian HM, **Meshinchi S**, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf S, Godwin JE, Willman CL, Pierce SA, List AF, Sandhu RK, Walter RB, Stirewalt DL, Appelbaum FR, Estey EH: A Scoring System for Prediction of *FLT3*-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 2590. Presenter: FO
 50. de Rooij JD, van den Heuvel-Eibrink MM, Hollink IH, Arentsen-Peters ST, Beverloo HB, van Galen JF, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmermann M, Alonzo TA, Pieters R, **Meshinchi S**, Zwaan CM: NUP98/JARID1A Is a New Recurrent Genetic Abnormality in Pediatric

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- Acute Megakaryoblastic Leukemia with a Distinct HOX-Gene Expression Pattern. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 537. Presenter: JdR
51. Ostronoff F, Alonzo TA, Gerbing RB, Loken MR, Pardo L, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Byron P, Lavey RS, Davies SM, Smith FO, Gamis AS, **Meshinchi S**: Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 529. Presenter: FO
 52. Ochs M, Farrar J, Considine M, Ries RE, Trevino LR, Alonzo TA, Guidry Auvil J, Davidsen TM, Gesuwan P, Muzney DM, Gamis AS, Wheeler DA, Helton HL, Smith MA, Gerhard DS, **Meshinchi S**, Arceci RJ: Genome Wide Promoter Methylation Patterns Predict AML Subtype Outcomes and Identify Novel Pathways Characterizing Diagnostic and Relapsed Disease in Children. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 1287. Presenter: MO
 53. Ostronoff F, Fitzgibbon M, McIntosh M, Ries RE, Gamis AS, Alonzo TA, Appelbaum FR, Stirewalt DL, **Meshinchi S**: RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 1278. Presenter: FO
 54. Gramatges MM, Alonzo TA, Gerbing RB, Bertuch AA, **Meshinchi S**: Constitutional Telomerase-Associated Gene Variants Associated with Chemotherapy-Related Toxicities in Pediatric Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 1403. Presenter: MG
 55. Ho PA, Alonzo TA, Gerbing RB, Sung L, Aplenc R, Pollard JA, Kuhn J, Heerema NA, Lange BJ, Gamis AS, **Meshinchi S**: *WT1* snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group. Blood (ASH Annual Meeting Abstracts), Nov 2012, 120: 1385. Presenter: PH
 56. Schechter T, Zaidman I, Chen H, Pollard J, **Meshinchi S**, Gassas A, Hitzler J, Abdelhaleem M, Ho R, Domm J, Woolfrey A, Frangoul H: The Outcome of Allogeneic Hematopoietic Cell Transplantation for Children with FLT3/ITD-Positive Acute Myelogenous Leukemia. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: HF
 57. Hirsch B, Alonzo T, Gerbing R, Kahwash S, Heerema-McKenney A, Aplenc R, Sung L, Winter L, Glick K, Davies S, Byron P, Lavey R, Wallas T, Smith F, Ho P, Gamis A, **Meshinchi S**, Raimond S: Abnormalities of 12p are Associated with High-Risk Acute Myeloid Leukemia: A Children's Oncology Group Report. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: BH
 58. Sung L, Aplenc R, Alonzo T, Gerbing R, **Meshinchi S**, Gamis A: Duration of Neutropenia is Associated with Reduced Relapse Risk in Children with De Novo Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: LS
 59. Gamis AS, Aplenc R, Alonzo TA, Sung L, **Meshinchi S**, Gerbing RB, Raimondi S, Hirsch B, Kahwash S, Heerema-McKenney A, Winter L, Glick K, Davies S, Byron P, Lavey R, Wallas T, Smith FO: Gemtuzumab Ozogamicin (GO) in children with *de novo* acute myeloid leukemia (AML) improves event-free survival (EFS) by reducing relapse risk – Results from the randomized Phase III Children's Oncology Group (COG) trial, AAML0531. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: AG

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

60. Horan J, Loken M, Alonzo T, Aplenc R, Gerbing R, Davies S, Gamis A, **Meshinchi S**: Impact of Residual Disease on Survival in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: JH
61. Tarlock K, Alonzo T, Loken M, Gerbing R, Aplenc R, Sung L, Raimondi S, Hirsch B, Gamis A, **Meshinchi S**: Disease Characteristics and Prognostic Implications of Cell Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia – A Report from Children’s Oncology Group. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: KT
62. Tarlock K, Blau A, Martins T, **Meshinchi S**: Identification of Novel Therapeutic Targets in FLT3/ITD Resistant Cells Through High Throughput Drug Screening. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: KT
63. Pollard J, Alonzo T, Gerbing R, Raimondi S, Hirsch B, Aplenc R, Gamis A, Loken M, **Meshinchi S**: Negative Prognostic Impact of High CD33 Expression is Negated with the Use of Gemtuzumab Ozogamicin: A Report from the Children’s Oncology Group. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: JP
64. Ostronoff F, Othus M, Gerbing R, Loken M, Raimondi S, Hirsch B, Lange B, Petersdorf S, Radich J, Appelbaum F, Gamis A, Alonzo T, **Meshinchi S**: NUP98/NSD1 Translocation Further Risk-Stratifies Patients with FLT3/ITD in Acute Myeloid Leukemia: A Report from Children’s Oncology Group and SWOG. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: FO
65. Ostronoff F, Othus M, **Meshinchi S**, Godwin J, Kopecky K, List A, Oehler V, Petersdorf S, Pogossova-Agadjanyan E, Radich J, Willman C, Appelbaum F, Stirewalt D: Prognostic significance of *NPM1* mutations in the absence of *FLT3*-ITD in older patients with AML: a SWOG report. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: FO
66. Kuhn J, Meerzaman D, Ries R, Milano F, Gamis A, Alonzo T, Guidry Auvil J, Davidsen T, Smith M, Gerhard D, Wai D, Arceci R, **Meshinchi S**: PIM3-SCO2 Fusion is a Novel Transcription-Induced Chimera That is Highly Prevalent in Childhood AML – Report from NCI/COG TARGET AML Initiative. Blood (ASH Annual Meeting Abstracts), Dec 2013. Presenter: JK
67. Johnston D, Rubnitz J, Alonzo T, Gerbing R, Aplenc R, Gamis A, **Meshinchi S**: An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? a Report from Children’s Oncology Group Protocols AAML0531 and 03P1 and St Jude Children’s Research Hospital Protocol AML02. Blood (ASH Annual Meeting Abstracts), Dec 2014. Presenter: DJ
68. Lim E, Trinh D, Ries R, Ma Y, Topham J, Hughes M, Pleasance E, Mungall A, Moore R, Zhao Y, Gerhard D, Oehler V, Kolb EA, Gamis A, Smith M, Alonzo T, Arceci R, **Meshinchi S**, Marra M: Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated With Treatment Resistance – A Report from the COG/NCI TARGET AML Initiative. Blood (ASH Annual Meeting Abstracts), Dec 2014. Presenter: EL
69. Chin D, Kutny M, Grim J, Gerbing R, Miller K, Farrar J, Auvil J, Smith M, Gerhard D, Davidsen T, Gesuwan P, Hermida L, Marra M, Mungall A, Moore R, Long W, Ma Y, Zong S, Kolb EA, Gamis A, Alonzo T, **Meshinchi S**: Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children’s Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative. Blood (ASH Annual Meeting Abstracts), Dec 2014. Presenter: DC

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

70. Kutny M, Alonzo T, Wang Y, Ries R, Farrar J, Auvil J, Smith M, Gerhard D, Davidsen T, Gesuwan P, Hermida L, Marra M, Mungall A, Moore R, Long W, Ma Y, Zong S, Kolb EA, Gamis A, **Meshinchi S**: *TET2* Mutations Are Highly Associated with RUNX1-RUNX1T1 Translocations and NPMc+ in Childhood AML: a Report from Children's Oncology Group AAML03P1, AAML0531 and NCI/COG Target AML Initiative. Blood (ASH Annual Meeting Abstracts), Dec 2014. Presenter: MK
71. Farrar J, Alonzo T, Ries R, Gerbing R, Auvil J, Davidsen T, Gesuwan P, Hermida L, Marra M, Mungall A, Mungall K, Ma Y, Long W, Zong, Kolb EA, Smith M, Gerhard D, Gamis A, **Meshinchi S**: *ASXL1* and *ASXL2* Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative. Blood (ASH Annual Meeting Abstracts), Dec 2014. Presenter: JF
72. Brodersen L, Alonzo T, Menssen A, Gerbing R, Pardo L, Voigt A, Kahwash S, Hirsch B, Raimondi S, Gamis A, **Meshinchi S**, and Loken M: A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531. Blood (ASH Annual Meeting Abstracts), Dec 2014. Presenter: LB
73. Loken M, Voigt A, Gerbing R, Brodersen L, Menssen A, Pardo L, Gamis A, Alonzo T, and **Meshinchi S**: Hierarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531. Blood (ASH Annual Meeting Abstracts), Dec 2014. Presenter: ML
74. Spitzer B, Guryanova OA, MD, Abdel-Wahab O, Kucine N, Adli M, Berman JN, **Meshinchi S**, Bernstein B, Pelosof R, Leslie C, Levine RL: Characterizing Transcriptional and Epigenetic Signatures Induced By FLT3-ITD Activation (ASH Annual Meeting Abstracts) , Dec 2014. Presenter: BS
75. Tarlock K, Todd A. Alonzo, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Aplenc R, Gamis AS, **Meshinchi S**: Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3-ITD+ Acute Myeloid Leukemia: A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts), Dec 2014. Presenter: KT
76. Ramamurthy R, Hughes MD, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Aplenc R, Gamis AS, Alonzo TA, **Meshinchi S**: Correlation of Mir-155 Expression with Clinical Outcome in Childhood AML: A Report from Children's Oncology Group. (ASH Annual Meeting Abstracts), Dec 2014. Presenter RR
77. Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, MS3, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, **Meshinchi S**, and Walter RB: Multimerin-1 (MMRN1) As Novel Adverse Prognostic Marker in Acute Myeloid Leukemia: A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts), Dec 2014. Presenter GSL
78. Schuback HL, Alonzo TA, Gerbing RB, Miller KL, Kahwash S, Heerema-Mckenney A, Hirsch BA, Raimondi SC, Aplenc R, Gamis AS, and **Meshinchi S**: CBFA2T3-GLIS2 Fusion Is Prevalent in Younger Patients with Acute Myeloid Leukemia and Associated with High-Risk of Relapse and Poor Outcome: A Children's Oncology Group Report. (ASH Annual Meeting Abstracts), Dec 2014. Presenter: HS

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

79. Kutny MA, Alonzo TA, Gerbing RB, Wang YC, Fu C, **Meshinchi S**, Gamis AS, Feusner JH and Gregory J: Arsenic Trioxide Is a Well Tolerated Consolidation Regimen in Children with Newly Diagnosed Acute Promyelocytic Leukemia; Toxicity Results of the Children's Oncology Group AAML0631 Trial. (ASH Annual Meeting Abstracts), Dec 2014. Presenter MAK
80. August KJ, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Horan JT, Alonzo TA, Gerbing RB, Wang YC, Kahwash S, Heerema-McKenney A, **Meshinchi S** and Gamis AS: Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes: A Report from the Children's Oncology Group Trials AAML03P1 and AAML0531. (ASH Annual Meeting Abstracts), Dec 2014. Presenter KJA
81. Dvinge H, Ries RE, Ilagan JO, Stirewalt DL, **Meshinchi S**, and Bradley RK: Sample Processing Obscures Cancer-Specific Alterations in Leukemic Transcriptomes. (ASH Annual Meeting abstracts), Dec 2014. Presenter RK Bradley
82. Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YC, Kahwash S, Heerema-McKenney A, **Meshinchi S**, and Gamis AS: Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) – Combined Results from the Children's Oncology Group (COG) Trials, AAML03P1 and AAML0531. (ASH Annual Meeting Abstracts), Dec 2014. Presenter EM Guest
83. Morris VA, Cummings V, **Meshinchi S** and Oehler V: Functional miRNA Expression Library Screen Identifies miRNAs That Alter Proliferation and Differentiation in Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts), Dec 2014. Presenter VA Morris
84. Johnston D, Rubnitz JE, Alonzo TA, Gerbing RB, Aplenc R, Gamis AS and **Meshinchi S**: An Analysis of CNS2 Patients with AML: Do They Require Additional Intrathecal Therapy? A Report from Children's Oncology Group Protocols AAML0531 and 03P1 and St Jude Children's Research Hospital Protocol AML02. (ASH Annual Meeting Abstract), Dec 2014. Presenter DJ
85. Maxson JE, Ries R, Wang YC, Gerbing RB, Kolb A, Thompson SL, Auvil JM, Marra, Ma Y, Zong S, Mungall AJ, Moore R, Long W, Gesuwan P, Davidsen TM, Hermida LC, Farrar JE, Radich JP, Smith MA, Gerhard DS, Gamis AS, Alonzo TA, and **Meshinchi S**: CSF3R Mutations Represent a Novel Therapeutic Target in Pediatric AML with a High Degree of Overlap with CEBPA Mutations: a Report from COG AAML0531 and COG/NCI Target AML Initiative. (ASH Annual Meeting Abstracts), Dec 2015. Presenter JEM
86. Brown F, Still E, Cifani P, Ficarro S, Pouliot G, Drill E Gonen M, He J, Balasubramanian S, Zhong S, Pavlick D, Yilmazel B, Krivtsov AV, Alonzo TA, **Meshinchi S**, Kornblau SM, Stone RM, Marcucci G, Byrd Jc, Levine RL, Armstrong SA, Gray N, Marto J, and Kentsis A: Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia. (ASH Annual Meeting Abstract), Dec 2015. Presenter FB
87. Chin D, Kutny MA, Grim J, Gerbing RB, Miller K, Farrar JE, M.D.5, Auvil J, Smith MA, Gerhard DS, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Mungall JE, Moore R, Long W, Ma Y, Zong S, Kolb A, Gamis AS, Alonzo TA, and **Meshinchi S**: Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative. (ASH Annual Meeting Abstract), Dec 2015. Presenter DC
88. Tarlock K, Hansen E, Hylkema T, Ries R, Farrar JE, Auvil J, Gerhard DS, Smith MA, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Mungall AJ, Mungall K, Ma Y, Zong S, Long W,

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- Boggon T, Alonzo TA, Kolb A, Gami AS, and **Meshinchi S**: Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. (ASH Annual Meeting Abstracts), Dec 2015. Presenter KT
89. Ostronoff F, Ries RE, Gerbing RB, Marra MA, Ma Y, Long W, Zong S, Mungall K, Andrew A, Gerhard DS, Smith MA, MD, PhD7, Gesuwan P, Davidsen TM, Hermida LC, Farrar JE, Auvil J, Raimondi SC, Hirsch BA, Kolb A, Gami AS, Alonzo TA, and **Meshinchi S**: Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative. (ASH Annual Meeting Abstracts), Dec 2015. Presenter FO
90. Kutny MA, Alonzo TA, Wang YC, Ries R, Farrar JE, Auvil J, Smith MA, Gerhard DS, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Mungall AJ, Moore R, Long W, Ma Y, Zong S, Kolb A, Gami AS, and **Meshinchi S**: TET2 Mutations Are Highly Associated with RUNX1-RUNX1T1 Translocations and NPMc+ in Childhood AML: A Report from Children's Oncology Group AAML03P1, AAML0531 and NCI/COG Target AML Initiative. (ASH Annual Meeting Abstracts), Dec 2015. Presenter MAK
91. Farrar JE, Alonzo TA, Ries RE, Gerbing RB, Auvil J, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Mungall JA, Mungall K, Ma Y, Long W, Zong S, Kolb A, Smith MA, Gerhard DS, Gami AS, MD, **Meshinchi S**: ASXL1 and ASXL2 Mutations in Childhood AML Are Strongly Associated with t(8;21) but Do Not Independently Impact on Prognosis: A Report from the Children's Oncology Group and NCI/COG Target Initiative. (ASH Annual Meeting Abstracts), Dec 2015. Presenter JEF
92. Lim EL, Trinh DL, Ries RE, Ma Y, Topham J, Hughes MD, Pleasance E, Mungall AJ, Moore R, Zhao Y, Gerhard DS, Oehler V, Kolb A, Gami AS, Smith MA, Alonzo TA, Arceci RJ, **Meshinchi S**, Marra MA: Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative. (ASH Annual Meeting Abstract) Dec, 2015. Presenter ELL
93. de Rooij J, Masetti R, van den Heuvel-Eibrink MM, Cayuela J, Trka J, Reinhardt D, Sonneveld E, Alonzo TA, Fornerod M, Zimmermann M, Pigazzi M, Pieters R, **Meshinchi S**, Zwaan CM, Locatelli F: Prognostic Relevance of Recurrent Genetic Aberrations in Pediatric Acute Megakaryoblastic Leukemia. (ASH Annual Meeting Abstracts) Dec 2015. Presenter JDR
94. Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gami AS, **Meshinchi S**, Walter RB: High Expression of Myocyte Enhancer Factor 2C (MEF2C) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts) Dec, 2015. Presenter RBW
95. Ostronoff F, Alonzo TA, Othus M, Kutny MA, Gerbing RB, Radich JP, Erba HP, Appelbaum FR, Kolb A, Gami AS, Stirewalt DL, **Meshinchi S**: Defining the Genomic Make up of Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): Report from COG AAML03P1, AAML531 and SWOG S0106. (ASH Annual Meeting Abstract) Dec, 2015. Presenter FO
96. Brodersen LE, Alonzo TA, Menssen AJ, Gerbing RB, Pardo L, Voigt AP, Kahwash SB, Hirsch BA, Raimondi SC, Gami AS, **Meshinchi S**, and Loken MR: A Recurrent Immunophenotype at Diagnosis Independently Identifies High Risk Pediatric AML: A Report from the Children's Oncology Group Trial AAML0531. (ASH Annual Meeting Abstracts) Dec, 2015. Presenter LEB

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

97. Pollard J, Alonzo TA, Gerbing RB, Wang YC, Joaquin J, Raimondi SC, Hirsch BA, Sung L, Aplenc R, Bernstein ID, Gamis AS, and **Meshinchi S**: Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531. (ASH Annual Meeting Abstracts) Dec, 2015. Presenter JP
98. Pollard J, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Aplenc R, Guest EM, Bernstein ID, Loken MR, **Meshinchi S**, and Gamis AS: Treatment of 11q23/MLL+ AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531. (ASH Annual Meeting Abstracts). Dec, 2015. Presenter JP
99. Voigt AP, Brodersen LE, Gerbing RB, Menssen AJ, Hirsch BA, Raimondi SC, Gamis AS, Alonzo TA, **Meshinchi S**, and Loken MR: Recurrent Genetic Abnormalities Are Reflected in Phenotype at Diagnosis in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group Protocol AAML0531. (ASH Annual Meeting Abstracts) Dec, 2015. Presenter APV
100. Loken MR, Voigt AP, Gerbing RB, Brodersen LE, Menssen AJ, Pardo L, Gamis AS, Alonzo TA, and **Meshinchi S**: Hierarchical Clustering of Immunophenotypic Cell Surface Antigen Expression Identifies Clinically Meaningful Cohorts in Childhood AML: A Report from the Children's Oncology Group Protocol AAML0531. (ASH Annual Meeting Abstracts) Dec, 2015. Presenter LEB
101. Kutny MA, Alonzo TA, Gerbing RB, Wang YC, Fu C, **Meshinchi S**, Gamis AS, Feusner JH, and Gregory J: Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631 Clinically Relevant Abstract. (ASH Meeting Abstracts) Dec, 2015. Presenter MAK
102. Lamba JK, Chauhan L, Aplenc R, Skrypek M, Pollard J, Alonzo TA, Wang YC, Bernstein ID, Gamis AS, and **Meshinchi S**: Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study. (ASH Annual Meeting Abstracts) Dec, 2015. Presenter JKL
103. Degrin M, Tarlock K, Agarwal A, **Meshinchi S**, Tognon CE, and Druker BJ: Novel Method to Perform Functional Drug Screens on Frozen Primary Leukemia Samples. (ASH Annual Meeting Abstracts) Dec, 2015. Presenter MD
104. Hughes MDH, Morris VA, Cummings C, **Meshinchi S**, and Oehler VG: KDM7A Is Targeted By MiR-155 in Acute Myeloid Leukemia and Impacts Differentiation. (ASH Annual Meeting Abstracts) Dec, 2015. Presenter MDH
105. Stoddard B, Garrett T, **Meshinchi S**, and Lamba J: Metabolomic Profiling Defines Distinct Metabolic Signature Associated with FLT3/ITD AML. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter SB
106. Le Q, **Meshinchi S**, Hadland BK, Walter RB, and Bernstein ID: The Role of Notch in Vascular Endothelial Cell-Mediated Protection of AML Precursors from Targeted Therapy. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter QL
107. Guest EM, Hirsch BA, Kolb EA, Alonzo TA, Gerbing R, Aplenc R, Pollard J, Sung L, **Meshinchi S**, Gamis AS, and Raimondi S: Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML)- Results from the Children's Oncology Group Trial AAML0531. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter EMG

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

108. Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, **Meshinchi S**, and Gamis AS: The Effect of Traumatic Diagnostic Lumbar Puncture in De Novo Pediatric Acute Myeloid Leukemia- A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter DLJ
109. Tarlock K, Cooper TM, Alonzo TA, Berging R, Pollard J, Aplenc R, Kolb EA, Gamis AS, and **Meshinchi S**: Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter KT
110. Kutny MA, Alonzo TA, Gerbing R, Wang Y-C, Fu C, Gamis AS, Kolb EA, Feusner JH, Gregory J, and **Meshinchi S**: FLT3 Mutations in Pediatric Acute Promyelocytic: A Report from The Children's Oncology Group AAML0631 Trial. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter MAK
111. Cooper TM, Gerbing RB, Alonzo TA, Pollard J, Sung L, Kolb EA, Aplenc R, **Meshinchi S**, and Gamis AS: Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter TMC
112. Tarlock K, Zong S, Ries RE, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto G, Vergillo J-A, Nguyen C, Chen Q, Meerzaman D, Kolb EA, Ross J, Mughal TI, Stephens P, Miller VA, **Meshinchi S**, and He J: Comprehensive Clinical Genomic Profiling Defines Age-Associated Molecular Targets in Pediatric and Adult Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter KT
113. Selim D, Alonzo TA, Othus M, Gerbing R, Ostronoff F, Tarlock K, Kutny MA, Aplenc R, Kolb EA, Radich JP, Appelbaum FR, Gamis AS, Stirewalt DL, and **Meshinchi S**: Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML- A COG and SWOG Intergroup Collaboration. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter DS
114. Pogosova-Agadjanyan EL, Moseley A, Wood BL, Appelbaum FR, Chauncey T, Chen I-M L, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Othus M, Radich JP, Willman CL, **Meshinchi S**, and Stirewalt DL: Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter ELP-A
115. Lamba JK, Chauhan L, Loken MR, Pollard J, Wang Y-C, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, and **Meshinchi S**: CD33 Splicing Polymorphism is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter JKL
116. Aplenc R, **Meshinchi S**, Sung L, Alonzo TA, Pollard J, Gerbing R, Raimondi SC, Hirsch BA, Loken MR, Winter L, Kahwash SB, Choi JK, Levine J, Kolb EA, and Gamis AS: The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter RA
117. Lim EL, Trinh DL, Ries RE, Wang J, Ma Y, Topham J, Hughes MD, Pleasance E, Mungall AJ, Moore R, Zhao Y, Kolb EA, Gamis AS, Gerhard DS, Alonzo TA, **Meshinchi S**, and Marra MA: A

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

- microRNA Expression-based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter ELL
118. Wilson ER, Brodersen LE, Zehentner BK, Menssen AJ, Voigt AP, Pardo L, Wells DA, Hitzler J, Berman JN, Alonzo TA, Kahwash SB, **Meshinchi S**, and Loken MR: Down Syndrome AML is Unique in Phenotype Both at Diagnosis and in Post Chemotherapy Regeneration. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter ERW
119. Farrar JE, Bolouri H, Ries RE, Triche TJ, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Guidry Auvil J, Davidsen TM, Gesuwan P, Hermida LC, Kolb EA, Gamis AS, Smith MA, Gerhard DS, and **Meshinchi S**: Marked Differences in the Genomic Landscape of Pediatric Compared to Adult Acute Myeloid Leukemia: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter JEF
120. Iacobucci I, Wen J, Meggendorfer M, Carmichael C, Choi JK, Masih K, Li Y, Payne D, Daisuke T, Kiyokawa N, Janke LJ, Alexander TB, Pounds S, Shi L, Valentine M, Basso G, Locatelli F, Yin SKK, Juh AYE, Rhonda RE, Stieglitz E, Wei A, Lewis ID, D'Andrea R, Kile BT, Zhang J, Loh ML, **Meshinchi S**, Haferlach T, and Mullighan C: The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter II
121. Ries RE, Bolouri H, Farrar JE, Lim EL, Triche TJ, Tarlock K, Auvil JG, Hirsch BA, Raimondi SC, Ma Y, Marra MA, Aplenc R, Guest EM, Kolb EA, Gamis AS, Smith MA, Gerhard DS, and **Meshinchi S**: Alteration of Chromatic Modifiers and Misregulation of Transcription Factors Devine the Genomic Profile of Infant AML. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter RER
122. Triche TJ, Farrar JE, Bolouri H, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Guidry Auvil JM, Davidsen TM, Gesuwan P, Hermida LC, Kolb EA, Gamis A, Smith M, Piccolo SR, Gerhard DS, and **Meshinchi S**: Divergent Epigenomes in Pediatric and Adult Acute Myeloid Leukemia Implicate cell of Origin and Transcriptional Silencing of Immune Responses As Sources of Clinically Relevant Heterogeneity: A Report from the Children's Oncology Group and NCI/COG Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter TJT
123. Tarlock K, Kaeding AJ, Alonzo TA, Loken MR, Ries RE, Pardo L, Gerbing R, Farrar JE, Guidry Auvil JM, Gerhard DS, Smith MA, Davidsen TM, Gesuwan P, Hermida LC, Marra MA, Mungall AJ, Mungall K, Ma Y, Zong S, Long W, Gamis AS, Kolb EA, and **Meshinchi S**: Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) as a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter KT
124. Alexander TB, Gu Z, Choi JK, Loh ML, Horan J, Buldini B, Basso G, Elitzur SC, Zwaan M, de Haas V, Yeoh AEJ, Reinhardt D, Tomizawa D, Lammens T, De Moerloose B, Zhou L, Hori H, Moorman AV, Moore AS, Hrusak O, **Meshinchi S**, Orgel E, Devidas M, Hunger SP, Guidry Auvil JM, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore R, Gerhard DS, Cao X, Shi L, Pounds S, Inaba H, and Mullighan C: Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. (ASH Annual Meeting Abstracts) Dec, 2016. Presenter ATB

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

125. Smith JL, Ries RE, Kolb EA, Alonzo TA, Gerbing RB, Ma Y, Marra MA, Bolouri H, **Meshinchi S**: The LSC17 Leukemic Stem Cell Signature Predicts Outcome in Pediatric Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2017. Presenter JLS
126. Tarlock K, Alonzo TA, Gerbing RB, Wang Y-C, Ries RE, Hylkema T, Joaquin J, Raimondi SC, Hirsch BA, Kolb EA, Gamis AS, **Meshinchi S**, Pollard JA: Functional Properties of Exon 17 KIT Mutations in Pediatric CBF AML Predict for Inferior Outcome and Enhanced Response to Tyrosine Kinase Inhibition: A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: KT
127. Ries RE, Smith JL, Triche T, Farrar JE, Alonzo TA, Ma Y, Wei L, Guidry Auvil J, Gerhard DS, Marra MA, Gamis AS, Kolb EA, Bolouri H, **Meshinchi S**: Evaluation of Cancer Testis Antigens (CTAs) As Immuno-Therapeutic Targets in Pediatric AM. (ASH Annual Meeting Abstracts) Dec 2017. Presenter RER
128. Cooper TM, Ries RE, Alonzo TA, Gerbing RB, Loken MR, Brodersen LE, Raimondi SC, Hirsch BA, Aplenc R, Gamis AS, Kolb EA, **Meshinchi S**: Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts) Dec 2017. Presenter TMC
129. Smith JL, Ries RE, Schuback HL, Brodersen LE, Loken MR, Bolouri H, **Meshinchi S**: Transcriptomic and Network Signatures of Cryptic Fusion *CBFA2T3-GLIS2* in Pediatric AML Reveals Clinical Considerations and Implications. (ASH Annual Meeting Abstracts) Dec 2017. Presenter JLS
130. Chauhan L, Alonzo TA, Wang J, Loken MR, Pollard JA, Aplenc R, Raimondi SC, Walter RB, Hirsch BA, Bernstein ID, Gamis AS, **Meshinchi S**, Lamba J: Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial. (ASH Annual Meeting Abstracts) Dec 2017. Presente: JL
131. Kaeding A, Pardo L, Loken MR, Brodersen LE, Tarlock K, **Meshinchi S**: Prolonged Azacitidine Exposure Alters Immunophenotype in Myeloid Leukemia Cell Lines. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: AK
132. Kaeding A, Tarlock K, Barwe S, Gopalakrisnapillai A, Alonzo TA, Gerbing RB, Loken MR, Ries RE, Pardo L, Chou C, Kolb EA, **Meshinchi S**: Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: AK
133. Tarlock K, Lamba J, **Meshinchi S**: CD33 DE2 Transcript Variant Encoded By Splicing Polymorphism Is Devoid of Antibody Binding Site and Lacks Response to CD33 Directed Antibody Drug Conjugates. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: KT
134. Tarlock K, Alonzo TA, Wang Y-C, Gerbing RB, Hylkema T, Ries RE, Hansen ME, Kolb EA, Gamis AS, **Meshinchi S**: Functional Evaluation and Clinical Implications of *FLT3* Juxtamembrane Domain Short Variants in Pediatric AML. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: KT
135. Fan Y, Hu Y, Nguyen C, Yan C, Ries RE, Bolouri H, Smith JL, Chen Q, Kolb EA, **Meshinchi S**, Meerzaman D: Altered Transcriptome Uniquely Associated with AML Vs. Normal Hematopoiesis. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: YF

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

136. Tarlock K, He Y, Sun J, Ries RE, Severson EA, Bailey M, Morley S, Balasubramanian S, Erlich R, Lipson D, Otto G, Vergillo J-A, Ross JS, Mughal T, Stephens P, Miller V, **Meshinchi S**, He J: Recurrent Copy Number Variants are Highly Prevalent in Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: KT
137. Lamba J, Chauhan L, Shin M, Loken MR, Pollard JA, Wang J, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gams AS, Alonzo TA, **Meshinchi S**: Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: JL
138. Kutny MA, Alonzo TA, Gerbing RB, Wang Y-C, Aplenc R, Gams AS, Feusner J, Woods WG, **Meshinchi S**, Johnston D: Outcomes Based on CNS Disease Status in Pediatric Acute Myeloid Leukemia and the Role of Peripheral Blood Contamination in Diagnostic Lumbar Punctures; A Report from the Children's Oncology Group Studies AAML0531 and AAML1031. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: MAK
139. Brodersen LE, Alonzo TA, Gerbing RB, Kolb EA, Gams AS, Aplenc R, **Meshinchi S**, Loken MR: Clinical Implications of Detection and Clearance of Post-Induction Residual Disease in 2119 Children and Young Adults with AML: Children's Oncology Group Studies AAML0531 and AAML1031. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: LEB
140. Noort S, Gerbing RB, Alonzo TA, Smith JL, Sonneveld E, Locatelli F, Reinhardt D, Baruchel A, Stary J, Van Den Heuvel-Eibrink MM, Zwaan CM, **Meshinchi S**: NUP98-KDM5A Fusion Gene Is Not Exclusive to Acute Megakaryoblastic Leukemia and Is an Independent Predictor of Poor Prognosis. (ASH Annual Meeting Abstracts) Dec 2017. Presenter: SN
141. Wei L, Trinh D, **Meshinchi S**, Marra MA: Single Cell Transcriptome Analysis Reveals Changing Levels and Distributions of Stemness across Disease States in Pediatric AML. (ASH Annual Meeting Abstracts) Dec 2017. Presenter WL
142. Foley A, Hughes SB, **Meshinchi S**, Maxson JE: CSF3R Mutations Synergize with CEBPA and SETBP1 Mutations in Acute Myeloid Leukemia and Chronic Neutrophilic Leukemia. (ASH Annual Meeting Abstracts) Dec 2017. Presenter JEM
143. Bezerra ED, Chien S, Martins T, Hammer C, Gardner KM, Sekizaki T, Rosen A, Shaw C, Oheler V, Blau CT, Lee S-I, Hendrie PC, Walter RB, Percival M-EM, Cassaday RD, Patay B, Carson A, **Meshinchi S**, Tarlock K, Appelbaum FR, Radich JP, Estey EH, Becker PS: Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned. (ASH Annual Meeting Abstracts) Dec 2017. Presenter BED
144. Ries RE, Leonti AR, Triche TJ, Gerbing RB, Hirsch BA, Raimondi SC, Smith JL, Cooper TM, Farrar JE, Deshpande AJ, Kolb, EA, Gams AS, Aplenc R, Alonzo TA, **Meshinchi S**. Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene – a COG/Tpaml Study. (ASH Annual Meeting Abstracts) Dec 2019. Presenter RER
145. Tarlock T, Brodersen LE, Alonzo TA, Wang Y-C, Gerbing RB, Pardo L, Dai F, Gams AS, Aplenc R, Pollard JA, Loken MR, **Meshinchi S**. CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2019. Presenter KT

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

146. Tarlock K, Alonzo TA, Wang Y-C, Gerbing RB, Ries RE, Hylkema TA, Woods WG, Cooper TM, Gamis AS, Aplenc R, **Meshinchi S**. Somatic Bzip Mutations of CEBPA Are Associated with Favorable Outcome Regardless of Presence As Single Vs. Double Mutation. (ASH Annual Meeting Abstracts) Dec 2019. Presenter KT
147. Lamble AJ, Brodersen LE, Alonzo TA, Wang J, Gerbing RB, Pardo L, Sung L, Tasian SK, Cooper TM, Kolb EA, Aplenc R, Loken MR, **Meshinchi S**. Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. (ASH Annual Meeting Abstracts) Dec 2019. Presenter AJL
148. Leonti AR, Pardo L, Alonzo TA, Gerbing RB, Brodersen LE, Ries RE, Smith JL, Le Q, Aplenc R, Kolb EA, Magnani JL, Fogler WE, Loken MR, **Meshinchi S**. Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML. (ASH Annual Meeting Abstracts) Dec 2019. Presenter ARL
149. Smith JL, Ries RE, Farrar JE, Alonzo TA, Gerbing RB, Leonti AR, Hylkema TA, Gamis AS, Aplenc R, Kolb EA, Nguyen C, Meerzaman D, Triche TJ, **Meshinchi S**. Long Non-Coding RNAs (lncRNAs) Are Highly Associated with Disease Characteristics and Outcome in Pediatric Acute Myeloid Leukemia – a COG and Tpaml Study. (ASH Annual Meeting Abstracts) Dec 2019. Presenter JS
150. Pogossova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen I-M L, Erba HP, Godwin JE, Jenkins IC, Fang M, Huynh M, Kopecky KJ, List AF, Naru J, Radich JP, Stevens E, Willborg BE, Willman CL, Wood BL, Zhang Q, **Meshinchi S**, Stirewalt D. Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report. (ASH Annual Meeting Abstracts) Dec 2019. Presenter DS
151. Tarlock K, Pollard JA, Alonzo TA, Gerbing RB, Wang Y-C, Ries RE, Smith JL, Kolb EA, Gamis AS, Aplenc R, **Meshinchi S**. Response to Sorafenib in FLT3/ITD AML Is Dependent on Co-Occurring Mutational Profile. (ASH Annual Meeting Abstracts) Dec 2019. Presenter KT
152. Pollard JA, Alonzo TA, Brown PA, Gerbing RB, Fox E, Choi JK, Fisher BT, Hirsch BA, Kahwash S, Levine JE, Loken MR, Raimondi SC, Tarlock K, Wood AC, Sung L, Kolb AE, Gamis AS, **Meshinchi S**, Aplenc R. Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031. (ASH Annual Meeting Abstracts) Dec 2019. Presenter JP
153. Gopalakrishnapillai A, Correnti C, Kisielewski A, Kaeding A, **Meshinchi S**, Kolb EA, Barwe S. Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity. (ASH Annual Meeting Abstracts) Dec 2019. Presenter SB
154. Gbadamosi M, Hylkema TA, **Meshinchi S**, Lamba JK. Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms. (ASH Annual Meeting Abstracts) Dec 2019. Presenter MG
155. Wei L, Ries RE, Plettner P, Mungall K, Mungall AJ, **Meshinchi S**, Marra MA. Transcriptome Analysis of Pediatric AML Reveals Non Protein-Coding RNAs Associated with Poor Survival Outcome and Treatment Resistance. (ASH Annual Meeting Abstracts) Dec 2019. Presenter LW

Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.

156. Gopalakrishnapillai A, Kaeding A, Schatz C, Sommer A, **Meshinchi S**, Kolb EA, Barwe S. In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2019. Presenter AG
157. Bolouri H, Johnson BK, Ries RE, Pardo L, Hylkema TA, Zhou W, Smith JL, Leonti AR, Kaeding A, Loken MR, Farrar JE, **Meshinchi S**, Triche TJ. A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies. (ASH Annual Meeting Abstracts) Dec 2019. Presenter HB
158. Kucine N, Leonti AR, Krishnan A, Ries RE, Levine RL, **Meshinchi S**. Transcriptome Profiling of Pediatric Myeloproliferative Neoplasms Demonstrates Dysregulation of Platelet-Relevant Genes and Enrichment of Inflammatory and JAK2 Mediated Complement Pathways. (ASH Annual Meeting Abstracts) Dec 2019. Presenter NK
159. Dahlberg A, Qayed M, Tarlock K, Pollard JA, Milano F, **Meshinchi S**, Delaney C. Demonstration of the Safety of Post Induction Infusion of Ex-Vivo Expanded Cord Blood Progenitor Cells in Pediatric Patients with Relapsed/Refractory Acute Myelogenous Leukemia. (ASH Annual Meeting Abstracts) Dec 2019. Presenter AD
160. Braun T, Coblenz C, Carratt SA, Okhovat M, Foley A, Schonrock Z, Nevenon K, Ries RE, McWeeney SK, Nerlov C, **Meshinchi S**, Carbone L, Druker BJ, Maxson JE. Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML. (ASH Annual Meeting Abstracts) Dec 2019. Presenter TB
161. Elsayed AH, Wu H, Cao X, Raimondi SC, Downing JR, Ribeiro R, Gruber TA, Ries RE, **Meshinchi S**, Rubnitz J, Pounds S, Lamba JK. A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome. (ASH Annual Meeting Abstracts) Dec 2019. Presenter AHE
162. Gbadamosi M, Elsayed AH, Ries RE, **Meshinchi S**, Lamba JK. Preliminary Lasso Regression Analysis Identifies DNA-Damage Gene Expression Signature Predictive of Clinical Outcomes in Patients Using Gemtuzumab Ozogamicin. (ASH Annual Meeting Abstracts) Dec 2019. Presenter MG
163. Hylkema TA, Pardo L, Loeb KR, Le Q, Imren S, Brodersen LE, Loken MR, **Meshinchi S**. CBFA2T3-GLIS2 induces Malignant Transformation of Primitive CD34+ Cord Blood Cells and Recapitulates Infant Megakaryocytic Leukemia. (ASH Annual Meeting Abstracts) Dec 2019. Presenter TAH
164. Underwood JG, Smith JL, Call LF, Tseng E, Hylkema TA, Ries RE, Leonti AR, Farrar JE, Triche TJ, **Meshinchi S**. Discovery of Novel IL3RA (CD123) Isoforms By Long Read Transcriptomics, Heterogeneous Expression Among AML Patient Cohorts and the Implications for Anti-CD123 Therapeutics. (ASH Annual Meeting Abstracts) Dec 2019. Presenter JGU
165. Longo L, Milano F, Delaney C, Bleakley M, Burroughs LS, Hadland B, Xue E, Roberts L, **Meshinchi S**, Mallhi KK, Thakar M, Baker KS, Summers C, Dahlberg A. Comparison of Outcomes between HSCT Donor Sources for Pediatric Patients with Hematologic Malignancies. (ASH Annual Meeting Abstracts) Dec 2019. Presenter LL
166. Huang BJ, Wang X, Harris M, Wandler A, Hwang E, Burgess M, Li Q, Severson P, Powell B, Kolb, Meshinchi S, Taylor B, Bollag G, Shannon K. Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML. (ASH Annual Meeting Abstracts) Dec 2020. Presenter BJH

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

167. Ries RE, Triche TJ, Smith JL, Leonti AR, Alonzo TA, Farrar JE, Chen X, Liu Y, Shaw T, Huang B, Wang Y, Gerbing RB, Hirsch B, Raimondi SC, Gamis AS, Aplenc R, Zhang J, Kolb EA, MA X, Meshinchi S. Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts. (ASH Annual Meeting Abstracts) Dec 2020. Presenter RER
168. Zarnegar-Lumley S, Alonzo TA, Othus M, Sun Z, Ries RE, Wang Y, Leonti AR, Kutny MA, Stirewalt D, Radich JP, Appelbaum FR, Pogossova-Agadjanyan EL, O'Dwyer KM, Erba HP, Abel-Wahab O, Tallman MS, Litzow M, Atallah EL, Luger SM, Levine RL, Cooper TM, Gamis AS, Aplenc R, Kolb AE, Meshinchi S Tarlock K. Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG. (ASH Annual Meeting Abstracts) Dec 2020. Presenter SZ
169. Bertrums EJM, Smith JL, Ries RE, Alonzo TA, Ostronoff F, Kaspers GJL, Hasle H, Zwaan CM, Hirsch BA, Raimondi SC, Cooper TM, Aplenc R, Gamis AS, Kolb EA, Goemans BF, Meshinchi S. The Molecular Characteristics and Clinical Relevance of NUP98-Other Translocations in Pediatric Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2020. Presenter EJMB
170. Brodersen LE, Hudson CA, Alonzo TA, Gerbing RB, Pardo L, Leonti AR, Singleton TP, Hsu , Lott LL, Dai F, Ghiradelli K, Kolb EA, Cooper TM, Pollard JA, Loken MR, Aplenc R, Meshinchi S. Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol. (ASH Annual Meeting Abstracts) Dec 2020. Presenter LEB
171. Huang BJ, Smith JL, Ries RE, Leonti AR, Crowgey EL, Furlan S, Shaw T, Wei L, Wang Y, Gerbing RB, Alonzo TA, Cooper TM, Kolb EA, Ma X, Farrar JE, Triche TJ, Meshinchi S. Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2020. Presenter BJH
172. Smith JL, Bertrums EJM, Ries RE, Ostronoff F, Leonti AR, Furlan SN, Goemans BF, Meshinchi S. The Transcriptomic Landscape of NUP98-Rearranged Pediatric Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2020. Presenter JLS
173. Le Q, Castro S, Tang TT, Loeb A, Leonti Ar, Pardo L, Loken MR, Correnti C, Meshinchi S. Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy. (ASH Annual Meeting Abstracts) Dec 2020. Presenter QL
174. Tarlock K, Meshinchi S, Rubnitz JE, Karol SE, Spitzer B, Sabnis AJ, Pathan A, Messahel B. Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access. (ASH Annual Meeting Abstracts) Dec 2020. Presenter KT
175. Higgins J, Lo FY, Hipp MJ, Valentine CC, Williams LN, Leonti AR, Ries RE, Radich JP, Meshinchi S, Huang BJ, Salk JJ. Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2020. Presenter JH
176. Tarlock K, Alonzo TA, Gerbing RB, Le Q, Tang TT, Hamill D, Gopalakrishnapillai A, Barwe S, Ries RE, Aplenc R, Wood AC, Kolb EA, Meshinchi S. Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia. (ASH Annual Meeting Abstracts) Dec 2020. Presenter KT

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

177. Leonti AR, Manselle M, Smith JL, Ries RE, Kolb AE, Meshinchi S. Target-Informed Repurposing of Immunotherapies in AML – a Transcriptome Based Approach for Identifying Immediately Available Therapeutics. (ASH Annual Meeting Abstracts) Dec 2020. Presenter ARL
178. Chandrasekaran D, Le Q, Prieve M, Stoltzman CA, Cook J, Blake JM, Massey EB, Meshinchi S, Delaney C. Generation of CAR-NK Cells Using a Notch-Mediated Cell Expansion and Differentiation Platform. (ASH Annual Meeting Abstracts) Dec 2020. Presenter DC
179. Wei L, Trinh D, Ries RE, Jin D, Corbett RD, Smith JL, Furlan SN, Meshinchi S, Marra MA. Integrative Analysis of Single-Cell RNA-Seq and ATAC-Seq Data across Treatment Time Points in Pediatric AML. (ASH Annual Meeting Abstracts) Dec 2020. Presenter LW
180. Nguyen NK, Elsayed AH, Meshinchi S, Lamba JK. An Ara-C, Daunorubicin, and Etoposide microRNA (ADEmiR) Score As a Prognostic Tool to Predict AML Treatment Outcomes. (ASH Annual Meeting Abstracts) Dec 2020. Presenter NKN

16. Other

National and International Invitational Lectures

1. Graduate Student Symposium of Pharmacological Sciences. The University of Michigan, Ann Arbor, MI. March 21st, 1987.
2. Fifteenth Annual Pharmacology Research Colloquium. The University of Michigan, Ann Arbor, MI. June 19th, 1987.
3. Graduate Student Symposium of Pharmacological Sciences. The University of Michigan, Ann Arbor, MI. March 26th, 1987.
4. Sixteenth Annual Pharmacology Research Colloquium. Michigan State University, East Lansing, MI. June 24th, 1988.
5. Meeting of the American Society for Pharmacology and Experimental Therapeutics. Montreal, Canada. (ASPET Travel Award Recipient). October 16th-20th, 1988.
6. Ninth International Symposium of the Journal of Steroid Biochemistry. Las Palmas, Canary Islands, Spain. May 28th-31st, 1989.
7. Interdepartmental symposium on Retinoic Acid Receptor, Hoffmann LaRoche Pharmaceuticals, Nutley, NJ. July, 1991.
8. First meeting of Children's Oncology Group (COG) biannual meeting, AML mini symposium, Role of FLT3/ITD in pediatric AML, Tampa, FL, Invited speaker. April, 2000.
9. Child Health Research Center (CHRC) annual meeting, Bethesda, MD. November, 2000.
10. Children's Oncology Meeting symposium on pediatric AML, Biannual meeting. Invited speaker, San Antonio. October, 2001.
11. Wayne State University research presentation. RTK activating mutations in AML. Invited Speaker, Detroit, MI. March, 2002.
12. University of Pennsylvania, Stem cell biology meeting. Biology of FLT3 activating mutations. Invited speaker, Philadelphia, PA. May, 2002.
13. Children's Hospital of Philadelphia, Pediatric Oncology seminar. Clinical implications of FLT3 activating mutations. Invited speaker, Philadelphia, PA. May, 2002.
14. Child Health Research Center (CHRC) annual meeting, St. Louis, MO. October, 2002.
15. Children's Oncology Group annual meeting, Young Investigator presentation, St. Louis, MO, Invited speaker. October, 2002.
16. Children's Oncology Group annual meeting, Infant Leukemia symposium, Invited speaker, St. Louis, MO, Invited speaker. October, 2002.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

17. Children's Hospital of Cincinnati, Department of pediatric hematology/oncology, Invited speaker, Cincinnati, OH. February 18th, 2003.
18. St. Jude Children's Research Hospital Grand Rounds, Invited speaker, Memphis, TN. November 13th, 2003
19. 47th international Symposium on Stem Cell & Hematopoiesis, Tokyo, Japan. October 23rd, 2004.
20. Children's Oncology Group Myeloid Biology Conference, Atlanta, GA. November 6th, 2004.
21. Children's Oncology Group Biology Conference, Invited speaker, COG National Conference, Los Angeles, CA. March 30th, 2005.
22. Children's Oncology Group Biopathology and Translational Research Symposium, Invited speaker, COG National Conference, Los Angeles, CA. March 30th, 2005.
23. Children's Oncology Group National Meeting, Invited speaker "Early progenitor involvement in AML" invited speaker, Los Angeles, CA. October, 2006.
24. Children's Oncology Group National Meeting, Invited speaker "Minimal residual disease in AML" invited speaker, Los Angeles, CA. October, 2006.
25. Children's Oncology Group National Meeting, "Prognostic significance of FLT3 mutations in pediatric AML" Invited speaker, Los Angeles, CA. October, 2006.
26. University of Minnesota Medical Center, Grand rounds, Invited Speaker, Minneapolis, MN. January 24th, 2007.
27. International meeting on "New horizons in the characterization and treatment of leukemia", Invited Speaker, Amsterdam, Netherlands. July 6th, 2007.
28. Lecture on molecular alterations in AML, COG National Meeting, Dallas, TX. April, 2007.
29. Children's Oncology Group National meeting, Risk Factors in Pediatric AML, Invited Speaker, Los Angeles, CA. April 4th, 2008.
30. Fanconi Anemia Research Fund Symposium, Hematopoietic Stem Cell Transplants for Bone Marrow Failure and for Acute Myeloid Leukemia in Fanconi Anemia. Invited speaker, Eugene, OR. October 3rd, 2008.
31. Children's Oncology Group Annual Meeting: Biology of AML. March 13, 2009
32. Emory University School of Medicine, AFLAC Cancer Center Visiting Professorship, "Molecular pathogenesis of AML", April 16, 2009.
33. 21st Annual Meeting of the International BFM Study Group, Genomic Alterations in Childhood AML, Invited Speaker, Antalya, Turkey, October 2010.
34. 21st Annual Meeting of the International BFM Study Group, Flow Cytometric MRD in AML, COG Experience, Invited Speaker, Antalya, Turkey, April 2010.
35. Baylor College of Medicine, Pediatric Hematology/Oncology Grand Rounds. "Contributions of Genomic Alterations to Disease Pathogenesis and Clinical Outcome in Acute Myeloid Leukemia", Invited Speaker, Houston, TX, May 2011.
36. 5th International EORTC-NCI-ASCO Annual Meeting, "FLT3 is a Stratification Factor for Targeted Therapy Treatments in Adult and Pediatric AML-Phase III Trials", Invited Speaker, Brussels, Belgium, October 2011.
37. "The NCI Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative: Using Large-Scale Genomics to Identify Novel Therapeutic Targets for Childhood Cancers", AACR Invited Speaker, AACR annual meeting, Chicago, IL, March 2012.
38. Children's Oncology Group Myeloid Disease Biology, Atlanta, GA, September 2012.
39. NCI Cancer Genomics, TARGET AML Initiative, Bethesda, MD, October, 2012.
40. Invited lectureship, Division of Hematology/Oncology/Bone Marrow Transplantation Children's Mercy Hospitals & Clinics, Stowers Institute for Medical Research, Kansas City, MO. November, 2012.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

41. NCI/ASCO/FDA initiative for use of minimal residual disease as a surrogate end point for response assessment in AML, Invited speaker, Bethesda, MD, March 4, 2013.
42. “Identification of Novel Therapeutic Targets for Childhood Cancers”, AACR Invited Speaker, AACR annual meeting, Washington DC, April 2013.
43. “Genomic Landscape in Childhood AML,” Translational Science Research Seminar Series, Alfred I. duPont Hospital for Children, Wilmington, DE, October 21, 2013.
44. “Targeting Genomic Alterations in AML,” Oncology Grand Rounds, University of Colorado School of Medicine, Children's Hospital Colorado Denver, CO, January 14, 2014.
45. 2nd Annual ASPHO/PBMTC Educational Meeting, “Biomarkers for Risk-Based Therapy in AML”, Invited Speaker, ASPHO Conference, Chicago, IL, May 13, 2014.
46. 31st Annual Meslissa Ann Krinsky Memorial Lecture, “Defining Genomic Landscape in Childhood AML-Implications for Clinical Intervention”, Grand Rounds Invited Speaker, Wayne State University, Children’s Hospital of Michigan, Detroit, MI, October 3, 2014.
47. “TARGET AML Initiative – Genomic Landscape in Childhood AML”, NCI TARGET Steering Committee Meeting, Bethesda, MD, October 9, 2014.
48. “The TARGET Project (Therapeutically Applicable Research to Generate Effective Treatments),” Guest Speaker, COG Cytogenetics Workshop, St. Louis, Missouri, April 24, 2015.
49. Invited Speaker, AROG Pharma, Biologic basis of FLT3 mutations in AML, Dallas, January 2016.
50. Invited Speaker, AML Think Tank, Defining biology of genomic alterations in AML. January 27th, 2017.
51. Invited Speaker, American Medical Informatics Association, A Perspective on Genomics in Clinical Practice: Focus on Pediatric Cancers, March 28th, 2017.
52. “New Risk Stratified in Pediatric AML” and “Novel Biomarker for Targeting in AML”, COG Biannual Meeting, March 30th, 2017.
53. “Genome and Epigenome of AML in Children and Young Adults”, Visiting Professorship, City of Hope Oncology Grand Rounds, May 17th, 2017.
54. “Genome and Epigenome of AML in Children and Young Adults”, Visiting Professorship, MD Anderson Cancer Center Grand Rounds, May 24th, 2017.
55. “Genome and Epigenome of AML in Children and Young Adults”, Visiting Professorship, AFLAC Cancer Center, Atlanta, June 13th, 2017.
56. “FLT3 Mutations and Mutational Spectrum in AML”, Invited Speaker, Educational Session, European Hematology Association, Madrid, Spain, June 2017.
57. Integrating New Molecular Targets in Acute Leukemias and Myeloproliferative Neoplasms, Invited as Forum Participant, Dallas, January 2018.
58. Visiting Professorship, Cole Foundation Research Day, McGill University, Montreal, Canada, May, 2018.
59. Invited Speaker, International Cancer Genome Consortium, Paris, France, May, 2018.
60. Invited Speaker, International BFM Leukemia Program, Helsinki, Finland, May, 2018.
61. Invited Speaker, 6th Global Summit on Hematologic Malignancies; Identifying Immunogenic Targets in AML; Whistler, BC, March 13-17, 2019
62. Invited Speaker, Therapeutic Advances in Childhood Leukemia & Lymphoma; Biology of AML in Children and Young Adults. Vancouver, BC, April 7-9, 2019
63. Invited Speaker, Seventh Annual PBMTC Educational Meeting: Advances in Cancer Therapy relating to Stem Cell Transplantation, “Biology of AML in Children and Young Adults” May 1, 2019, New Orleans, Louisiana
64. Invited Speaker, Pediatric Bone Marrow Transplant Consortium Annual Meeting, “Genomic classification of AML in children and young adults”, May 3, 2019, New Orleans, Louisiana

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

65. Invited Speaker, Children's Oncology Group National Meeting; Novel therapeutic targets in AML. September 12, 2019, Atlanta, GA
66. Invited Speaker, Childhood Cancer Data Initiative, Invited Speaker, National presentation, "Challenges in data use in childhood AML", National Cancer Institute, Bethesda, MD, July 29-31, 2019.
67. Invited Speaker, National Cancer Institute Downs Syndrome Initiative, Planning a Virtual Down Syndrome Cohort Across the Lifespan, Bethesda, MD, Sept 23-24 2019
68. Invited Speaker, Baylor Medical Center/Texas Children's Cancer and Hematology Centers, 2nd Symposium on Childhood Cancer Health Disparities Conference, "Genomic and Biologic Variations Underlying Disparities and Outcomes in Childhood AML"; Houston, Texas; November 4, 2019
69. Invited Speaker, International Congress of Bone Marrow Transplant "Molecular Landscape of Pediatric AML." Seoul, Korea; September 10 -12, 2020

Local

1. Pediatric Hematology/Oncology Conference. Children's Hospital and Regional Medical Center, Seattle, WA. May 1999.
2. Fred Hutchinson Cancer Research Center Grand Rounds, Invited Speaker, Seattle, WA. February, 2002.
3. Children's Hospital and Regional Medical Center, Department of Pediatric Hematology/Oncology, Oncology seminar, Seattle, WA. January, 2003.
4. Children's Hospital and Regional Medical Center, Pediatric Hem/Onc Conference, Seattle, WA. November 21, 2003.
5. Fred Hutchinson Cancer Research Center, Clinical Research Division Seminar, Seattle WA. September 27, 2004.
6. Children's Hospital and Regional Medical Center, Dept. of Hematology/Oncology Divisional meeting, "Molecular Alterations in AML," Seattle, WA. January 11, 2008.
7. Fred Hutchinson Cancer Research Center Grand Rounds, "Molecular Alterations and Significance of Homologous Recombination in AML Pathogenesis," Seattle, WA, March 4, 2008.
8. University of Washington Institute for Stem Cell and Regenerative Medicine, Inaugural Stem Cell Retreat at SLU. "Early progenitors and molecular evolution in AML," Invited Speaker, Seattle, WA. November 4, 2008.
9. Fred Hutchinson Cancer Research Center Grand Rounds, "Risk and Target based therapy and novel biologic approaches in AML," Seattle, WA, February 24, 2009.
10. Fred Hutchinson Cancer Research Center Program in Epidemiology, Introduction to Cancer Biology presentation: "Molecular Therapeutics in Cancer." Invited speaker, Seattle, WA, May 17, 2010.
11. Fred Hutchinson Cancer Research Center, Special Presentation Sponsored by Complete Genomics. "Whole Human Genome Sequencing of AML," Invited Speaker, Seattle, WA, May 17, 2011.
12. University of Washington Hematology Grand Rounds, Invited Speaker, Seattle, WA, November 2011.
13. Seattle Children's Hospital, Hematology/Oncology Grand Rounds, "Genomic and Epigenomic Alterations in AML," Seattle, WA, October 4, 2013.
14. Fred Hutchinson Cancer Research Center Grand Rounds, "Evolving AML Genome," Seattle, WA, February 4, 2014.
15. Seattle Children's Hospital, Grand Rounds, "AML: Evolving Landscape", April 7th, 2017.

**Fred Hutchinson Cancer Research Center
Curriculum Vitae
Soheil Meshinchi, M.D., Ph.D.**

16. Fred Hutchinson Cancer Research Center, Grand Rounds Speaker, Genome and Epigenome of AML in Children and Young Adults, May 1st, 2017.
17. “Western Regional Summit on Acute Leukemias (AML, ALL, MPN)”, Invited Panelist, Seattle, October 6th, 2018.
18. Fred Hutchinson Cancer Research Center; AML Spore Presentation, “Discovery and Immunotherapeutic Targeting of AML-Restricted Antigens” July 12, 2019, Seattle, WA
19. University of Washington Hematology Grand Rounds, “Biologic approached to AML therapy” March 29, 2019, Seattle, WA
20. Seattle Children’s Hospital, Hematology/Oncology Grand Rounds, “Genomics of childhood AML” Seattle, WA, October 18, 2019